STATE OF HAWAI'I | KA MOKU'ĀINA O HAWAI'I DEPARTMENT OF ACCOUNTING AND GENERAL SERVICES | KA 'OIHANA LOIHELU A LAWELAWE LAULĀ

OFFICE OF ENTERPRISE TECHNOLOGY SERVICES | KE'ENA HO'OLANA 'ENEHANA

P.O. BOX 119, HONOLULU, HAWAII 96810-0119

May 15, 2025

The Honorable Ronald D. Kouchi President of the Senate and Members of the Senate Thirty-Third State Legislature State Capitol, Room 409 Honolulu, Hawai'i 96813 The Honorable Nadine K. Nakamura Speaker and Members of the House of Representatives Thirty-Third State Legislature State Capitol, Room 431 Honolulu, Hawai'i 96813

Aloha Senate President Kouchi, Speaker Nakamura, and Members of the Legislature:

Pursuant to HRS section 27-43.6, which requires the Chief Information Officer to submit applicable independent verification and validation (IV&V) reports to the Legislature within ten days of receiving the report, please find attached the report the Office of Enterprise Technology Services received for the State of Hawai'i, Department of Health, BHA Integrated Case Management System Project.

In accordance with HRS section 93-16, this report may be viewed electronically at http://ets.hawaii.gov (see "Reports").

Sincerely,

Christine M. Sakuda Chief Information Officer State of Hawai'i

Attachments (2)





Hawaii BHA Integrated Case Management System Project – Phase 4

IV&V Report for the period of

April 1 – April 30, 2025

Final Submitted: May 14, 2025



Agenda

Executive Summary IV&V Findings & Recommendations

Appendices

- A Rating Scales
- B Inputs
- C Project Trends
- D Acronyms and Definitions
- E List of Production Defects





The project continues to make good progress in enhancing the BHA Inspire system and has recently gone live with significant functionality with regards to Adverse Event Reporting (AER) to help them better track and address the quality of the service their vendors provide to their customers. The new AER modular solution is now live in production, and users are reporting positive feedback on the new functionality. The project hopes this modular solution will help them identify unreported adverse events more effectively.

Two high-severity post-production defects were resolved during this reporting period, including one related to an external Microsoft service error that was outside of the project's control. Despite early licensing challenges, the project onboarded a testing expert this month to repair, develop, and rewrite automated scripts and assess regression test processes, and is expecting to boost BHA testing productivity and improve system testing quality and velocity.

BHA is actively working to secure additional Business Analyst resources. Despite their current lack of resources, BHA continues to make steady progress in documenting some system workflows and operational procedures for help desk staff so they can better support their users.

The project is working to improve the governance process for production system restarts and has recently drafted a production system restart protocol that could help to ensure timely and effective communication to stakeholders and minimize system outages and disruptions. BHA has provided some key changes to the governance document, including adjustments to the advance notice period, provider notifications, and specific language preferences, which would further strengthen the protocol and enhance its effectiveness.

The project has reported progress in the improvement of some previously reported system performance issues. IV&V has closed a related finding (#33) as users are no longer reporting performance concerns.



Feb	Mar	Apr	Category	IV&V Observations			
G	G	G	Sprint Planning	IV&V was invited to attend the DDD Backlog Prioritization Meeting. Several key items were discussed, including Apple Health, Calculator, Provider, and Customer Portal Documents. While the meeting addressed these items, many of the backlog items still require estimation. DDD is currently working to complete these estimations. IV&V is reducing the risk rating from medium to low due to the progress made in backlog prioritization and ongoing efforts to complete estimations.			
G	G	G	User Story (US) Validation	There are no active findings in the User Story (US) Validation category, which remains Green (low criticality) for this reporting period. IV&V will continue to monitor the US development and validation process in upcoming reporting periods.			
Y	Y	Y	Test Practice Validation	Regression testing was successfully executed from 3/25/2025 to 4/2/2025. CAMHD executed manual and automated tests, while DDD conducted manual regression testing. In April 2025, the project onboarded a Tosca Automated Regression Testing SME. The overall approach for automated regression testing will be finalized by the end of April 2025, with execution continuing through May 2025. The INSPIRE project will have an updated suite of automated test scripts, along with knowledge transfer and training for the identified DDD staff.			



Feb	Mar	Apr	Category	IV&V Observations
Y	Y	Y	Release / Deployment Planning	Two high-severity post-production defects were resolved during this reporting period, including one related to an external Microsoft service error that was outside of the project's control.



Feb	Mar	Apr	Category	IV&V Observations	
G	G	G	On-The-Job- Training (OJT) and Knowledge Transfer (KT) Sessions	This category remains Green (low criticality) for the April reporting period with no active findings.	
G	G	G	Targeted KT	is category remains Green (low criticality) for the April reporting period. IV&V will ntinue to monitor.	
G	G	G	Project Performance Metrics	here are no project performance metrics to report for the April reporting period. IV&V rill keep this category's criticality rating Green (low criticality) and will continue to nonitor.	
G	G	G	Organizational Maturity Assessment (OMA)	This category remains Green (low criticality) for the April reporting period. There are no outstanding findings in this category, and IV&V will continue to monitor.	




Feb	Mar	Apr	Category	IV&V Observations
Y	√	Y	Project Management	The project continues to make good progress in enhancing the BHA Inspire system and has recently gone live with significant functionality with regards to Adverse Event Reporting (AER) to help them better track and address the quality of the service their vendors provide to their customers. The new AER modular solution is now live in production, and users are reporting positive feedback on the new functionality. The project hopes this modular solution will help them identify unreported adverse events more effectively. The project is working to improve the governance process for production system restarts and has recently drafted a production system restart protocol that could help to ensure timely and effective communication to stakeholders and minimize system outages and disruptions. BHA has provided some key changes to the governance document, including adjustments to the advance notice period, provider notifications, and specific language preferences, which would further strengthen the protocol and enhance its effectiveness.



Feb	Mar	Apr	Category	IV&V Observations
Y	Y	Y	Resource Management	BHA is actively working to secure additional Business Analyst resources. Despite their current lack of resources, BHA continues to make steady progress in documenting some system workflows and operational procedures for help desk staff so they can better support their users.
				Despite early licensing challenges, the project onboarded a testing expert this month to repair, develop, and rewrite automated scripts and assess regression test processes, and is expecting to boost BHA testing productivity and improve system testing quality and velocity.



As of the April 2025 reporting period, Nine (9) open findings were updated – Seven (7) Medium Issues, One (1) Medium Risk and One (1) Low Issue, spread across the Release/Deployment Planning, Test Practice Validation, Sprint Planning, Project Management, Resource Management, assessment areas are currently open.



Assessment Categories

Throughout this project, IV&V verifies and validates activities performed in the following process areas:

- Sprint Planning
- User Story Validation
- Test Practice Validation
- Release / Deployment Planning
- On-the-Job Training (OJT) and Knowledge Transition (KT) Sessions
- Targeted Knowledge Transition (KT)
- Project Performance Metrics
- Organizational Maturity Assessment
- Project Management
- Resource Management



Sprint Planning (cont'd)

#	Key Findings	Criticality Rating
	Medium Risk: The absence of separate dedicated product backlog review meetings can lead to unclear priorities, misalignment with stakeholders, inadequate refinement, and an increased risk of scope creep.	
	Update : IV&V was invited to attend the DDD Backlog Prioritization Meeting. Several key items were discussed, including:	
41	- Apple Health	
	- Calculator	
	- Provider and Customer Portal Documents	
	While the meeting addressed these items, many of the backlog items still require estimation. DDD is currently working to complete these estimations. IV&V is reducing the risk rating from medium to low due to the progress made in backlog prioritization and ongoing efforts to complete estimations.	

Recommendations	Status
CAMHD and DDD implement a structured feedback management process with a prioritization framework to ensure that all new requests are thoroughly evaluated and aligned with project goals before being added to the backlog.	Open
Separate dedicated product backlog review meetings (during Sprints) would allow clarifying any ambiguities or uncertainties, re-prioritization, estimation and refinement of backlog items. This would allow the project team to avoid situations where decisions about including items mid-Sprint would have to be taken.	Open
IV&V recommends scheduling separate dedicated product backlog review meetings (during Sprints) where all relevant stakeholders are invited to review the product backlog and scheduled at the appropriate time(s) such that there is sufficient time to plan the design, development, and implementation (DDI) of the next release(s).	Open

Test Practice Validation

#	Key Findings	Criticality Rating
	Medium Issue: As a result of regression testing not being consistently performed, production releases are breaking existing functionality in the production environment.	
	Finding Update: R4.11 Regression testing was successfully executed from 3/25/2025 to 4/2/2025. CAMHD executed both manual and automated tests, while DDD carried out manual regression testing.	M
2	In April 2025, the project onboarded a Tosca Automated Regression Testing SME. The overall approach for automated regression testing will be finalized by the end of April 2025, with execution continuing through May 2025. The INSPIRE project will have an updated suite of automated test scripts, along with knowledge transfer and training for the identified DDD staff.	

Recommendations	Status
To ensure effective Tosca testing, it is crucial for both divisions to align on a unified resource allocation strategy. Given the limited availability of resources, open communication and consensus-building are essential for optimizing tester utilization. By collaborating to prioritize testing efforts, share critical test cases, and identify overlapping areas, the divisions can achieve comprehensive regression testing without overburdening a single resource. This collaborative approach will balance workloads, streamline processes, and enhance test coverage, minimizing delays and bottlenecks. Ultimately, it will enable both divisions to efficiently meet their testing objectives.	Open
A balanced approach that combines manual and automated regression testing to ensure broad test coverage and flexibility.	Open



Test Practice Validation (cont'd)

Recommendations	Status
Having board(s) in Azure DevOps or a document on SharePoint that provides information about the status of regression testing automation, to facilitate visibility and transparency to BHA project personnel and stakeholders.	In Progress
Schedule priorities should be reevaluated by distributing the work according to the resource bandwidth. This will ensure that the schedule is not impacted and that the work is done efficiently between regression testing and Golden Record (GR) tasks.	In Progress
Pursue and complete additional formal training in Azure DevOps and Tricentis for test automation as soon as possible and complete efforts to automate the two primary regression test scripts.	In Progress
Determine if current regression testing timeframes are adequate, and if not, add more time to the pre-production regression test efforts for all release deployments.	In Progress



Test Practice Validation (cont'd)

#	Key Findings	Criticality Rating
40	Medium Issue: Limited testing processes can lead to poor-quality software, project delays, and extended user acceptance testing. Finding Update: R4.11 was successfully deployed on 4/3/2025, with Smoke Testing successfully completed on 4/4/25. A Mid-Sprint Deployment (MSD) was also performed on 4/18/25, which included four (4) User Stories. Additional unresolved production defects have been identified following the R4.11 deployment, and the project team is currently working to confirm the number of new defects. The project team continues to address other outstanding production defects (see Appendix E for details). The project team has enhanced smoke test scripts to provide more comprehensive coverage, including functionality such as the Provider Portal. To further strengthen quality assurance, the project onboarded a Tosca automated regression testing expert in early April 2025, with work scheduled to begin shortly thereafter. This regression testing effort is expected to span April and May 2025. The expert will focus	M

Recommendations	Status
Make efforts to implement a streamlined Root Cause Analysis (RCA) process to identify the causes of defects and prevent recurrence. Due to project resource constraints, propose timeboxing RCA efforts for each defect introduced into production. Timeboxing involves allocating a fixed period (e.g., 1-2 hours per defect or a set number of hours per week) for focused Root Cause Analysis (RCA) activities. These activities may include quickly gathering defect context, analyzing potential causes, and proposing corrective actions, all within the specified timeframe. Project PM(s) can oversee the tracking of corrective actions to ensure completion.	Open



Test Practice Validation (cont'd)

Recommendations	Status
IV&V has requested an overview of the testing process, with a focus on process such as tracking test coverage and requirements traceability.	In Progress
A Stakeholder Register helps identify and understand all project stakeholders, ensuring needs are met and risks are managed through effective communication. A RACI matrix clarifies roles and responsibilities, improving collaboration, decision-making, and resource management, which are all critical for the success of IT projects.	In Progress
Identify stakeholders (output is Stakeholder Register) and develop a RACI matrix for testing.	In Progress
Review the overall testing process and implement any needed improvements identified.	Open

Release / Deployment Planning (cont'd)

#	Key Findings	Criticality Rating
39	Low Issue: Due to on-going deployment processes and technical execution issues, the Project may continue to encounter defects and challenges, e.g., when releases are in production or in meeting projected timelines for production and non-production deployments. Finding Update: R4.11 was successfully deployed on 4/3/2025, with Smoke Testing successfully completed on 4/4/25. A Mid-Sprint Deployment (MSD) was also conducted on 4/18/25, which included four (4) User Stories. One earlier high-severity defect was traced to a Microsoft service error and was resolved on 4/18/25. A second high-severity issue was later identified as deployment-related. While an RCA was documented and shared via email, the issue was not logged in Azure DevOps (ADO) as per standard procedures and was instead tracked informally. The team has acknowledged this and is taking steps to align more closely with established processes moving forward. Additional unresolved production defects have been identified following the R4.11 deployment, and the project team is currently working to confirm the number of new defects. Root Cause Analyses (RCAs) are not currently being consistently documented for production defects, and the project team acknowledges the value of establishing a formal RCA process, and further discussions are planned. Implementing a robust RCA process may help reduce defect recurrence by addressing unresolved or unidentified root causes. IV&V will continue to monitor the deployment quality of R4.11, FHIR, MSDs, and the AER solution to identify any deployment-related defects.	L
Rec	ommendations	Status
recu set n	ement a streamlined Root Cause Analysis (RCA) process to identify deployment causes and prevent rence. To manage resource constraints, consider timeboxing RCA efforts—e.g., 1–2 hours per defect or a umber of hours weekly. Within this timeframe, focus on gathering context, analyzing causes, and proposing ective actions. Project PMs can track these actions to ensure follow-through.	Open
faste	project should consider automating deployments for resource savings, increased efficiency, consistency, r time to market, improved collaboration and reliability, scalability, version control integration, and rollback bility.	Open

Release / Deployment Planning (cont'd)

Recommendations	Status
Implement a streamlined Root Cause Analysis (RCA) process to identify deployment causes and prevent recurrence. To manage resource constraints, consider timeboxing RCA efforts—e.g., 1–2 hours per defect or a set number of hours weekly. Within this timeframe, focus on gathering context, analyzing causes, and proposing corrective actions. Project PMs can track these actions to ensure follow-through.	Open
The project should consider automating deployments for resource savings, increased efficiency, consistency, faster time to market, improved collaboration and reliability, scalability, version control integration, and rollback capability.	Open
Ensure there are adequate and qualified resources to support the current deployment processes. This may require support from RSM resources to provide assistance and knowledge transfer for some more complex deployment components.	Open
As appropriate, consult with RSM on best practices that BHA could employ to support deployment.	Open
Request the assistance of the RSM Solution Architect in reviewing and correcting issues associated with the consistency of configurations across environments, ensuring that the test environment is capable of testing ALL functions of any given release without the need for using multiple test environments.	Open
Request assistance from the RSM Solution Architect in reviewing deployment scripts to double-check for accuracy and completeness before commencing deployment activities.	Open
The Project Team should consider evaluating potential changes to improve/enhance existing processes and communications to address current release/deployment shortfalls.	Open

Release / Deployment Planning (cont'd)

Recommendations	Status
IV&V recommends performing a Root Cause Analysis (RCA) in collaboration with RSM for the continued concerns surrounding environment differences.	Open
IV&V recommends updating the Project's Configuration Management Plan to address the current needs of the Project. This should include specific checklists geared at ensuring repeatable promotional processes by DOH.	Open
Look at implementing 'hard' code freeze dates as well as test environment deployment dates to ensure that testing and deployment activities are not rushed.	Open
Ensure an operational and fully functional test environment is available to effectively conduct end-to-end regression testing prior to deploying a release to production.	Open
Develop a plan to institutionalize the execution of smoke testing for promotions to non-production and production environments. This will help to ensure that all components needed to test have been properly deployed prior to the actual execution of test activities.	Open



#	Key Findings	Criticality Rating
	Medium Issue: Due to multiple quality concerns, the project may continue to face impactful system defects.	
14	Finding Update: R4.11 was successfully deployed on 4/3/2025, with Smoke Testing successfully completed on 4/4/25. A Mid-Sprint Deployment (MSD) was also performed on 4/18/25, which included four (4) User Stories.	M
	One of the two previously reported high-severity defects was resolved and deployed with R4.11. The second issue appeared to be related to a Microsoft service error and was resolved on 4/18/25, when Microsoft performed a rollback. Additional unresolved production defects have been identified following the R4.11 deployment, and the project team is currently working to confirm the number of new defects. The project team continues to address other outstanding production defects (see Appendix E for details). BHA is currently prioritizing higher-severity tasks, which have delayed the resolution of lower-priority issues; however, remediation efforts remain ongoing. IV&V will closely monitor R4.11, FHIR implementation, any Mid-Sprint Deployments (MSDs), and the AER solution.	
Recon	nmendations	Status
	oject have discussions around utilizing tools such as SonarQube for continuous inspection of code quality tablishing a source code quality threshold to maintain high-quality, secure, and maintainable code.	Open
-	oject increases comprehensive testing prior to joint testing to reduce the burden on BHA testers and post-production defects.	Open
	vendor add a "Found In" column to the daily scrum file to indicate the environment where each defect entified.	In Progress
The SI	vendor provides the total number of defects in production and reports these numbers regularly to BHA.	In Progress

Recommendations	Status
Evaluate existing project staff skills and experience levels to ensure they meet BHA support requirements.	In Progress
Perform CAMHD revenue neutrality fiscal balance testing on a quarterly basis to ensure revenues are as expected.	In Progress



#	Key Findings	Criticality Rating
33	Low Issue: Performance bottlenecks with the INSPIRE production environment may result in low productivity and poor user experience. Finding Update: The production system performance of both the AER solution and INSPIRE remained stable during this reporting period, with no issues reported. As a result, IV&V will close this finding.	Closed
Rec	ommendations	Status
5/20	V recommends: BHA execute a performance test during the development of R4.6 (planned completion 0/2024), identifying test cases and scenarios that include both DDD and CAMHD functionality, sactions/functionality that are performance intensive, e.g., calculator functionality	Closed
	duct load and performance testing for each release that has significant new features/functionality, e.g., culator-related transactions.	Open
Crea	ate a plan for comprehensive performance testing and address any performance bottlenecks.	Open
Hav	e the benchmark assessments done annually and implementation of Azure App Insights for Power Platform.	Open
	cute test scripts that measure the run-time for execution of long-running transactions. E.g., Calculator stionality/transactions and monitoring results over time.	Open



#	Key Findings	Criticality Rating
	Medium Issue: Lack of effective governance and communication among stakeholders can have significant negative impacts on a project in several ways.	M
42	Update: Communication between the various areas supporting the INSPIRE project has seen positive progress. One area that could benefit from further attention is the coordination and reporting of testing activities, which will help ensure even smoother collaboration moving forward. IV&V will continue monitoring governance for an additional month.	

Recommendations	Status
Establish a mutual understanding of the contractual terms and conditions: BHA and the SI have discussions to align on a shared understanding of the contractual terms and conditions for the INSPIRE project.	Closed
Create a Governance Structure: Implement a governance structure that defines decision-making processes, escalation procedures, and accountability mechanisms. Clarify how decisions will be made, who has authority, and how issues will be resolved.	Open
Develop a Stakeholder Registry, RACI Matrix, and Stakeholder Engagement Plan: Identify key stakeholders and develop a plan to engage them throughout the project lifecycle. Tailor communication strategies to address the needs and preferences of different stakeholders, ensuring their active involvement and support.	Open
Clearly Define Roles and Responsibilities: Clearly outlining the roles and responsibilities of each stakeholder involved in the project, would ensure that everyone understands their duties and how they contribute to the project's success.	Open



Recommendations	Status
Encourage Open Communication and Feedback: Foster a culture of open communication and feedback where stakeholders feel comfortable sharing their thoughts, concerns, and suggestions. Encourage constructive dialogue and actively seek input to improve decision-making and problem-solving. Keep stakeholders informed about project progress, milestones, and key developments through regular updates and progress reports. Highlight achievements, challenges, and any changes to the project plan or scope.	Open
Resolve Conflicts Promptly: Address conflicts and disagreements among stakeholders promptly and professionally. Encourage dialogue, active listening, and compromise to find mutually acceptable solutions that support project goals.	Open
Manage Expectations: Manage stakeholders' expectations by setting realistic timelines, budgets, and deliverables. Foster a culture of transparency about project constraints and risks and proactively communicate any changes or deviations from the plan.	Open
Evaluate and Adapt: Continuously evaluate the effectiveness of governance and communication processes and adjust as needed. Solicit stakeholders' feedback to identify areas for improvement and continuously refine your approach.	Open



#	Key Findings	Criticality Rating
46	Medium Issue: Lack of oversight of the established defect management process could lead to lost/forgotten defects and user frustration and could slow the resolution of similar defects in the future. Finding Update: IV&V has reviewed the documentation outlining the Help Desk process. IV&V continues to observe increased project focus on both the Help Desk and defect management processes and will monitor adherence to these processes while providing feedback and recommendations based on best	M
	practices. Meanwhile, BHA is reviewing the previously provided Help Desk documentation and considering adopting and enforcing the outlined defect management procedures.	

Recommendations	Status
 IV&V recommends to: Send communications to the project stakeholders to clarify the defect management process and the importance of logging all defects. Take steps to assure current and new users understand how to report and/or log defects. Consider designating a defect management lead or champion to oversee adherence to the process and assure all defects are logged. Keep stakeholders informed about defect status, priority, impacts, and resolution timelines. This could increase awareness of the importance of logging defects. Discuss ways to improve the defect logging and management process with the SI and come up with a plan to improve. 	Open



#	Key Findings	Criticality Rating
47	Medium Issue: The lack of a governance process for restarting production systems can impact service availability and frustrate end-users and hinder accountability. Finding Update: BHA is continuing with the development of a document describing a communication protocol. DDD has provided some key changes, including adjustments to the advance notice period, provider notifications, and specific language preferences, which would further strengthen the protocol and enhance its effectiveness.BHA shared the draft document with DDD and IV&V for initial review.	M

Recommendations	Status
 IV&V recommends BHA Develop standard procedures for system restarts, including pre-checks, step-by-step instructions, and post-restart verifications. Require formal approvals before initiating a restart, especially for INSPIRE, and document all actions in a centralized system. Define clear escalation paths for when restarts do not go as planned, including identifying contacts for technical support and management approval for additional interventions. Automate Restart Procedures where possible. The governance process is established, it should be effectively communicated to the project team. Provide stakeholders with a clear explanation of the reason for the restart and the lessons learned, while documenting the restart details in the defect record. 	Open



Resource Management

#	Key Findings	Criticality Rating
	Medium Issue: A shortage of BHA project resources could lead to reduced productivity and project delays.	
34	Finding Update: To address a few of the resource challenges the project has faced, in early April 2025, DDD onboarded a Tosca Automated Regression Testing Subject Matter Expert (SME). To support a successful onboarding, DDD provided system demos, training materials, and facilitated collaboration with the CAMHD and SI team. Internal DDD resources have been identified for knowledge transfer related to regression testing. This will enable an effective transition for maintaining the automated testing suite. Additionally, CAMHD and DDD are actively working to identify and secure resources to support the Business Analyst roles.	M

Recommendations	Status
Utilizing peer-to-peer knowledge sharing, allowing experienced team members to informally share their expertise during team meetings. Additionally, creating internal documentation that outlines best practices and processes for developing security policies would serve as a self-service resource for the team.	Open
DDD and CAMHD have further discussions to optimize resource utilization between the two divisions.	Open
BHA should explore options for offloading project team members' daily responsibilities to other staff.	In Progress

Resource Management (cont'd)

Recommendations	Status
BHA should work quickly to create new positions and receive State approval.	In Progress
BHA should identify tasks and duties that they can ask the SI to assume, as permitted by the contract, which are presently being handled by BHA members.	In Progress
BHA should explore the use of contractors to fulfill the functions for open project positions.	In Progress



IV&V Findings & Recommendations Project Performance Metrics

Metric	Description	IV&V Observations	IV&V Updates				
	Review and validate the velocity data as reported by the		Velocity Metric Trends:				
Velocity	 verify the project is on pace to hit the total target number of US/USP 	April: R4.11 was deployed to production on 4/3/2025 and a mid-sprint deployment with four (4) User Stories followed on 4/18/2025.	Release	Planned velocity	Actual velocity	Percentage attained	
			R4.11	111	103	93	

Phase 4 Releases Cumulative Variance

Release	Planned velocity	Actual velocity	Cumulative variance
R4.1	309	114	-195
R4.2	85	174	-106
R4.3	85	124	-67
Golden Record Mid-Sprint (MSD)	0	68	1
R4.4	240	225	-14
R4.5	95	76	-33
R4.6	84	103	-14
R4.7	111	50	-75
R4.8	111	107	-79
R4.9	111	71	-119
R4.10	111	162	-68
R4.11	1 11	103	-76



Project Performance Metrics (cont'd.)

Metric	Description	IV&V Observations	IV&V Updates
Defect Metrics	 Understand and track the following: Defects by category (bug fixes) USPs assigned to defects in a release vs. USPs assigned to planned US in a release 	April - Velocity was estimated at 111 USPs for R4.11, 103 R4.11 USPs were promoted to production on 4/3/25. 23 of the 103 USPs were for defect fixing. •78% of the USPs were associated with user stories and requests. •22%* of the total USPs were associated with defects encountered during the release effort or pulled from the defect backlog.	The defect percentage for April was 22%* which is over the target range of 20% or less of all USPs promoted to production.

Note*: This defect percentage does not include defects under warranty that are assigned zero (0) User Story Points.

Appendix A: IV&V Rating Scales

Appendix AIV&V Rating Scales

This appendix provides the details of each finding and recommendation identified by IV&V. Project stakeholders are encouraged to review the findings and recommendations log details as needed.

- See Findings and Recommendations Log (provided under separate cover)
- IV&V Assessment Category Rating Definitions

The assessment category is under control and the current scope can be delivered within the current schedule.

The assessment category's risks and issues have been identified, and mitigation activities are effective. The overall impact of risk and issues is minimal.

The assessment category is proceeding according to plan (< 30 days late).

The assessment category is under control but also actively addressing resource, schedule or scope challenges that have arisen. There is a clear plan to get back on track.

The assessment category's risk and/or issues have been identified, and further mitigation is required to facilitate forward progress. The known impact of potential risks and known issues are likely to jeopardize the assessment category.

Schedule issues are emerging (> 30 days but < 60 days late).

Project leadership attention is required to ensure the assessment category is under control.

The assessment category is not under control as there are serious problems with resources, schedule, or scope. A plan to get back on track is needed.

The assessment category's risks and issues pose significant challenges and require immediate mitigation and/or escalation. The project's ability to complete critical tasks and/or meet the project's objectives is compromised and is preventing the project from progressing forward.

Significant schedule issues exist (> 60 days late). Milestone and task completion dates will need to be re-planned. Executive management and/or project sponsorship attention is required to bring the assessment category under control.



R

Appendix A

Finding Criticality Ratings

Criticality Rating	Definition
B	A high rating is assigned if there is a possibility of substantial impact to product quality, scope, cost, or schedule. A major disruption is likely, and the consequences would be unacceptable. A different approach is required. Mitigation strategies should be evaluated and acted upon immediately.
M	A medium rating is assigned if there is a possibility of moderate impact to product quality, scope, cost, or schedule. Some disruption is likely, and a different approach may be required. Mitigation strategies should be implemented as soon as feasible.
D	A low rating is assigned if there is a possibility of slight impact to product quality, scope, cost, or schedule. Minimal disruption is likely, and some oversight is most likely needed to ensure that the risk remains low. Mitigation strategies should be considered for implementation when possible.





Appendix B

Inputs

This appendix identifies the artifacts and activities that serve as the basis for the IV&V observations.

Meetings attended during the April 2025 reporting period:

- 1. Daily Scrum Meetings
- 2. Daily Design Meetings
- Twice Weekly RSM Issues Meeting
- 4. Weekly BHA-ITS Program Status Meeting
- 5. Bi-Weekly Check-in: CAMHD
- 6. Bi-Weekly Check-in: DDD
- 7. BHA (CAMHD & DDD) IV&V Joint Meeting
- 8. IV&V Draft IV&V Status Review Meeting with DOH
- 9. DOH BHA IT Solution Project Steering Committee
- 10. US# Testing & Request Items
- 11. AER Analytics Bi-weekly Meeting

Eclipse IV&V® Base Standards and Checklists



Artifacts reviewed during the April 2025 reporting period:

- 1. Daily Scrum Notes
- 2. Twice Weekly Issues Meeting Notes
- 3. Weekly BHA-ITS Program Status Report
- 4. Release 4.7 Release Notes

Appendix C: Project Trends

Appendix C Project Trends

				_						
	July	August	September		November	December		February		
User Story Validation										
Test Practice Validation										
Sprint Planning Release /										
Deployme nt Planning										
OJT and KT Sessions Targeted										
Project Performan										
Organizati onal Maturity Metrics										
General Project Manageme nt										
Resource Manageme nt										
Total Open Findings	12	12	14	14	14	14	14	11	10	9
Issue - high Issue -	0	0	0	0	0	0	0	0	0	0
medium_ Issue -	8	8	10	10	10	10	10	7	9	7
low_ Risk -	0	0	0	0	0	0	0	0	0	0
high Risk -	2	2	2	2	2	2	2	1	1	1
medium Risk - low	0	0	0	0	0	0	0	0	0	1
Preliminar y Concern_	1	1	2	2	2	2	2	0	0	0



Appendix D Acronyms and Definitions

Acronyms	Definition Definition
DOH	Department of Health
ВНА	Behavioral Health Services Administration
CAMHD	Child & Adolescent Mental Health Division
FHIR	Fast Healthcare Interoperability Resources
DDI	Design Development Implementation
DDD	Developmental Disabilities Division
SI	System Integrator
USP	User Story Points
SME	Subject Matter Expert
SIT	System Integration Testing
MS	Microsoft
MSD	Mid Sprint Deployment
ADO	Azure DevOps
SLA	Service Level Agreement
RCA	Root Cause Analysis
UAT	User acceptance testing
OJT	On-the-Job Training
KT	Knowledge Transition
SFTP	Secure File Transfer Protocol
IV&V	Independent Verification and Validation
MQD	Med-QUEST Division
CMS	Centers for Medicare & Medicaid Services
AER	Adverse Events Report



Appendix E List of Production Defects

ID 🔻 Work 🕶	Divisi	Title	State	Prior Severity	Found -	Created Date ▼ RCA Categories
30634 Bug	CAMHD	CAMHD Bug - Credentialing documents not copied into PROD during Data Migration	Completed in QA_Test	t 3 3 - Medium	PROD	2/16/2021 15:45
30726 Bug	DDD	Portal signature fields do not accept touchscreen input	Evaluated_On Hold	2 3 - Medium	PROD	9/17/2021 9:07
33550 Bug	CAMHD	Bug: "Progress Notes Associated to Invoices" page not loading	New	3 3 - Medium	PROD	3/31/2023 17:11
33841 Bug	DDD	Bug - Calculator 3.0 - Users able to schedule service past ISP end date again	Pending Approval	3 3 - Medium	PROD	5/17/2023 8:22
34110 Bug	DDD	Bug - Individual Budget unlinking from Service Authorizations	Pending Approval	2 3 - Medium	PROD	7/27/2023 15:40
34238 Bug	CAMHD	BUG - Assessment Entity Initial Save Time - IMHE	Evaluated_On Hold	2 3 - Medium	Prod	8/17/2023 2:33
34242 Bug	DDD	Bug - Case Merge - Contact Notes not merging; Permissions error	New	3 3 - Medium	PROD	8/17/2023 8:44
34969 Bug	DDD	DDD - Duplicate Provider Plans	Completed in QA_Test	t 1 3 - Medium	PROD	2/23/2024 5:58
		DDD - Cal3.0 - BiMonthly Recurrence authorization not taking into account Unit of				
35278 Bug	DDD	Service	Pending Approval	2 3 - Medium	PROD	6/3/2024 11:53
35317 Bug	DDD	DDD - Plan Services with no Provider Plan	Active	2 3 - Medium	PROD	6/24/2024 9:06
35450 Bug	DDD	DDD - Calculator not printing correctly	Pending Approval	2 3 - Medium	PROD	7/26/2024 8:36
36383 Bug	DDD	DDD - Calculator problem with paid base and add on	New	2 3 - Medium	PROD	9/26/2024 9:19
36854 Bug	DDD	DDD - Inspire - backed up ISP in the wrong place	Ready for Code Review	w 1 3 - Medium	PROD	10/31/2024 3:13
		Both - "On deactivation of Plan Service - deactivate related Provider Plan Service Flow"				
37186 Bug	Both	issue	Completed in QA_Test	t 1 3 - Medium	PROD	12/6/2024 9:10 Environmental Discrepancie
37663 Bug	DDD	DDD - Data Update to Account for Missing Provider Plan Value on Plan Service	Completed in QA_Test	t 1 3 - Medium	PROD	1/23/2025 8:01
37694 Bug	DDD	DDD - TCM batch file date is different in PROD from other environments	Pending Approval	2 3 - Medium	PROD	1/29/2025 8:25
37733 Bug	DDD	DDD - Incorrect Columns displaying on Provider Plan subgrid (Action Plan tab of ISP)	Evaluated_On Hold	1 3 - Medium	PROD	2/5/2025 5:37
37791 Bug	DDD	DDD - CIT Referral: Create Document Location Flow Failures	Pending Approval	2 3 - Medium	PROD	2/10/2025 9:30
37793 Bug	DDD	DDD - ISP Report Generation Issues	New	2 3 - Medium	PROD	2/10/2025 10:06
38391 Bug	DDD	DDD - Inspire AER - RN signature disappears	Completed in QA_Test	t 2 3 - Medium	PROD	2/27/2025 8:27
38496 Bug	DDD	DDD - CMU Supervisor DashboardLOC subgrid is blank	Completed in QA_Test	t 1 3 - Medium	PROD	3/5/2025 4:24 Design Errors
38529 Bug	DDD	DDD - AER Remediation Plan of Action Print Name field	Completed in QA_Test	t 2 3 - Medium	PROD	3/10/2025 3:31 Design Errors
38625 Bug	DDD	DDD - Calculator mid-year changes not saving	New	2 3 - Medium	PROD	3/14/2025 8:14
		CAMHD - Remove single quotes in texts in Provider Referral "Selected for Service":				
39412 Bug	CAMHD	Creation of Sub-folders in Provider Portal Document flow	Completed in QA_Test	t 2 3 - Medium	PROD	3/20/2025 10:20
39797 Bug	DDD	DDD - AER entry error when Provider tried to submit the AER	New	2 3 - Medium	PROD	4/16/2025 5:29





Solutions that Matter

ID	Short Description	Finding Statement	Analysis and Significance	Recommendation	Finding Update	Category	Туре	Priority	Status	Closure Reason	Closed Date	Identified Date	Owner	
2	Regression testing	As a result of	R3.3 introduced a	To ensure effective Tosca testing, it is	4/30/25 - R4.11 Regression testing was successfully executed from 3/25/2025 to 4/2/2025. CAMHD executed both	Test Practice	Issue	Medium	Open			12/31/2019	Gautam Gulvady	
		regression testing not	defect that	crucial for both divisions to align on a	manual and automated tests, while DDD carried out manual regression testing.	Validation							-	
		being consistently		unified resource allocation strategy. Given	In April 2025, the project onboarded a Tosca Automated Regression Testing SME. The overall approach for									
		performed,	production specific to	the limited availability of resources, open	automated regression testing will be finalized by the end of April 2025, with execution continuing through May 2025.									
		production releases are breaking existing	Integrated Support and Life Trajectory	communication and consensus-building are essential for optimizing tester utilization.	The INSPIRE project will have an updated suite of automated test scripts, along with knowledge transfer and training for the identified DDD staff.									
		functionality in the		By collaborating to prioritize testing	Tor the identified DDD staff.									
		production	informed IV&V that	efforts, share critical test cases, and	3/31/25 -The SI has updated the AER regression test scripts. Regression testing for R4.11 began on 3/25/25 and is									
		environment.	there are other	identify overlapping areas, the divisions	scheduled for completion by 4/2/25. For this release, CAMHD will perform both manual and automated testing,									
			examples of	can achieve comprehensive regression	while DDD will primarily focus on manual regression testing. To ensure continued support for future Phase 4									
			functionality being	testing without overburdening a single	releases—R4.12 and beyond—the project will be onboarding a Tosca Automated Regression Testing Subject Matter									
			deprecated after a	resource. This collaborative approach will	Expert (SME) in early April 2025, with work scheduled to begin subsequently. This effort is expected to take place in									
			release, some of	balance workloads, streamline processes,	April and May 2025. Upon completion, the INSPIRE project will have a fully updated and comprehensive set of									
			which are still being	and enhance test coverage, minimizing	automated test scripts. Additionally, documentation, knowledge transfer, and training will be provided to the DDD									
			report. IV&V has not	delays and bottlenecks. Ultimately, it will enable both divisions to efficiently meet	staff to ensure they can effectively maintain and update the scripts going forward.									
			evaluated the	their testing objectives.	2/28/25 - Regression Testing for R4.11 is scheduled from 3/25/2025 to 4/2/2025. CAMHD will perform both manual									
			project's root cause	their testing objectives.	and automated tests, while DDD will focus exclusively on manual regression testing. To support future Phase 4									
			analysis (RCA) process	2. A balanced approach that combines	releases, including R4.11 and beyond, the project will onboard a Tosca Automated Regression Testing SME, with the									
			used to determine	manual and automated regression testing	work set to begin on 3/10/2025. The SI has uploaded and executed one regression test case for the AER project and									
			why such functionality	to ensure broad test coverage and	is preparing additional regression test scripts with estimated completion before the R4.11 go-live.									
			was deprecated but	flexibility.										
			will discuss further		1/31/25 - Regression Testing for R4.10 is scheduled from 1/29/2025 to 2/5/2025. One defect (view on the DDD									
			with BHA in January	3. Having board(s) in Azure DevOps or a	supervisor dashboard) has come out of regression testing. CAMHD will conduct a mix of manual and automated									
			2020.	document on SharePoint that provides	testing, while DDD will focus on manual regression testing. To support future Phase 4 releases beyond R4.10, the									
			Thorough vetting and validation of	information about the status of regression testing automation, to facilitate visibility	project plans to onboard a Tosca automated regression testing Subject Matter Expert (SME). The plans and timeline									
			regression test cases	and transparency to BHA project personnel	for Tosca automated regression testing are being reviewed, with plans to commence work on 3/1/2025. For the AER project, the SI is preparing to conduct regression testing on AER functionality.									
			are necessary to	and stakeholders.	project, the sets preparing to conduct regression testing on Ack functionality.									
			prevent defects when	and statemoraers.	12/31/24 - R4.9 regression testing was conducted manually from 11/25/2024 to 12/4/2024, identifying one (1)									
			a release is pushed	4. IV&V recommends reevaluating the	defect. However, users encountered three (3) production defects in R4.9. IV&V remains concerned about the									
			live. When defects	schedule priorities by distributing the work	exclusive reliance on manual regression testing, which poses risks such as inefficiencies, human error, limited test									
			occur in production,	according to the resource bandwidth. This	coverage, and dependency on specific testers. IV&V recommends investing in automated regression testing to									
14	Code quality	Due to multiple	the project should System defects	will ensure that the schedule is not IV&V recommends:	enhance efficiency, reduce the hurden on RHA staff, and improve product quality. 4/30/25 - R4.11 was successfully deployed on 4/3/2025, with Smoke Testing successfully completed on 4/4/25. A	Project Management	Iccup	Medium	Open			9/30/2020	Gautam Gulvady	
17	coue quanty	quality concerns, the	identified in August	Closer collaboration between divisions	Mid-Sprint Deployment (MSD) was also performed on 4/18/25, which included four (4) User Stories.	1 Toject Wanagement	13300	Wediam	Орен			5/50/2020	Gautain Galvady	
		project may continue	that affected claims	to review reported defects, ensuring a	One of the two previously reported high-severity defects was resolved and deployed with R4.11. The second issue									
		to face impactful	were due to multi-	shared understanding and alignment,	appeared to be related to a Microsoft service error and was resolved on 4/18/25, when Microsoft performed a									
		system defects.	faceted quality issues	particularly regarding the severity and	rollback. Additional unresolved production defects have been identified following the R4.11 deployment, and the									
			were individually	priority of production defects.	project team is currently working to confirm the number of new defects. The project team continues to address other									
			addressed during this		outstanding production defects (see Appendix E for details). BHA is currently prioritizing higher-severity tasks, which									
			reporting period.	2. The project utilize tools such as	have delayed the the resolution of lower-priority issues; however, remediation efforts remain ongoing. IV&V will									
			IV&V notes that there is one remaining	SonarQube for continuous inspection of code quality and establishing a source code	closely monitor R4.11, FHIR implementation, any Mid-Sprint Deployments (MSDs), and the AER solution.									
			defect still being	quality threshold to maintain high-quality,	3/31/25 - The AER solution is in production. The project team closely monitored the solution to ensure stability,									
			evaluated that affects	secure, and maintainable code.	quickly resolve issues, and help users adjust to the new system (also known as Hypercare); Hypercare ended on									
			a limited number of	, , , , , , , , , , , , , , , , , , , ,	3/21/25 and the project is prioritizing the product backlog. The AER team worked diligently to close all defects									
			claims. Overall, the	3. The project increases comprehensive	reported during Hypercare. The AER solution's progress is being discussed in regular meetings between key	1	1			1		1		
			Project Team has	testing prior to joint testing to reduce the	stakeholders.	1	1			1		1		
			responded with a	burden on BHA testers and reduce post-	Since the deployment of R4.10 on 2/6/25, the project has identified additional unresolved production defects,	1	1			1		1		
			commitment to	production defects.	including 1 high-severity defect, in Azure DevOps (ADO) (see Appendix E for details). BHA is prioritizing higher-priority	1	1			1		İ		
		1	increase project	1	tasks, which has delayed the resolution of these lower-priority issues, although remediation efforts are underway.		1			1		1		
			quality and is in the	A. The SI wender add a "Found Ir" actions										
			quality and is in the	4. The SI vendor add a "Found In" column to the daily scrum file to indicate the	The R4.11 go-live is scheduled for 4/3/25. IV&V continues to express concern about code quality and will closely									
			quality and is in the process of identifying improvements to	The SI vendor add a "Found In" column to the daily scrum file to indicate the environment where each defect was	The R4.11 go-live is scheduled for 4/3/25. N&V continues to express concern about code quality and will closely monitor R4.10, FHIR, any MSDs, and the AER solution.									
			process of identifying	to the daily scrum file to indicate the										
			process of identifying improvements to	to the daily scrum file to indicate the environment where each defect was	monitor R4.10, FHIR, any MSDs, and the AER solution.									
			process of identifying improvements to associated testing processes. These currently include:	to the daily scrum file to indicate the environment where each defect was identified. 5. The SI vendor provides the total number	monitor R4.10, FHIR, any MSDs, and the AER solution. 2/28/25 - R4.10 was deployed to production on 2/6/2025. That same day, users reported a critical defect, prompting the deployment of a hotfix with a workaround on 2/7/2025. Following the deployment of R4.10, the project has recorded five additional unresolved production defects: two high									
			process of identifying improvements to associated testing processes. These currently include: Performing Revenue	to the daily scrum file to indicate the environment where each defect was identified. 5. The SI vendor provides the total number of defects in production and reports these	monitor R4.10, FHIR, any MSDs, and the AER solution. 2/28/25 - R4.10 was deployed to production on 2/6/2025. That same day, users reported a critical defect, prompting the deployment of a hotfix with a workaround on 2/7/2025. Following the deployment of R4.10, the project has recorded five additional unresolved production defects: two high severity, two medium severity, and one low severity, in Azure DevOps (ADO)—(see Appendix E for details). BHA is									
			process of identifying improvements to associated testing processes. These currently include: Performing Revenue Neutrality Testing to	to the daily scrum file to indicate the environment where each defect was identified. 5. The SI vendor provides the total number	monitor R4.10, FHIR, any MSDs, and the AER solution. 2/28/25 - R4.10 was deployed to production on 2/6/2025. That same day, users reported a critical defect, prompting the deployment of a hotfix with a workaround on 2/7/2025. Following the deployment of R4.10, the project has recorded five additional unresolved production defects: two high severity, two medium severity, and one low severity, in Azure DevOps (ADO)—(see Appendix E for details). BHA is prioritizing higher-priority tasks, which has delayed addressing these lower-priority defects, though remediation									
			process of identifying improvements to associated testing processes. These currently include: Performing Revenue Neutrality Testing to ensure expected	to the daily scrum file to indicate the environment where each defect was identified. 5. The SI vendor provides the total number of defects in production and reports these numbers regularly to BHA.	monitor R4.10, FHIR, any MSDs, and the AER solution. 2/28/25 - R4.10 was deployed to production on 2/6/2025. That same day, users reported a critical defect, prompting the deployment of a hotfix with a workaround on 2/7/2025. Following the deployment of R4.10, the project has recorded five additional unresolved production defects: two high severity, two medium severity, and one low severity, in Azure DevOps (ADO)—(see Appendix E for details), BHA is prioritizing higher-priority tasks, which has delayed addressing these lower-priority defects, though remediation efforts are underway. Additionally, the AER solution went live on 2/21/2025 and a Mid-Sprint Deployment (MSD)									
			process of identifying improvements to associated testing processes. These currently include: Performing Revenue Neutrality Testing to ensure expected revenue streams are	to the daily scrum file to indicate the environment where each defect was identified. 5. The SI vendor provides the total number of defects in production and reports these numbers regularly to BHA. 6. The project evaluate existing project	monitor R4.10, FHIR, any MSDs, and the AER solution. 2/28/25 - R4.10 was deployed to production on 2/6/2025. That same day, users reported a critical defect, prompting the deployment of a hotfix with a workaround on 2/7/2025. Following the deployment of R4.10, the project has recorded five additional unresolved production defects: two high severity, two medium severity, and one low severity, in Azure DevOps (ADO)—(see Appendix E for details). BHA is prioritizing higher-priority tasks, which has delayed addressing these lower-priority defects, though remediation efforts are underway. Additionally, the AER solution went live on 2/21/2025 and a Mid-Sprint Deployment (MSD) with 2 new items were deployed the same day. The R4.11 go-live is scheduled for 4/3/2025. N&V remains concerned									
			process of identifying improvements to associated testing processes. These currently include: Performing Revenue Neutrality Testing to ensure expected revenue streams are largely unchanged	to the daily scrum file to indicate the environment where each defect was identified. 5. The SI vendor provides the total number of defects in production and reports these numbers regularly to BHA. 6. The project evaluate existing project staff skills and experience level to ensure	monitor R4.10, FHIR, any MSDs, and the AER solution. 2/28/25 - R4.10 was deployed to production on 2/6/2025. That same day, users reported a critical defect, prompting the deployment of a hotfix with a workaround on 2/7/2025. Following the deployment of R4.10, the project has recorded five additional unresolved production defects: two high severity, two medium severity, and one low severity, in Azure DevOps (ADO)—(see Appendix E for details), BHA is prioritizing higher-priority tasks, which has delayed addressing these lower-priority defects, though remediation efforts are underway. Additionally, the AER solution went live on 2/21/2025 and a Mid-Sprint Deployment (MSD)									
			process of identifying improvements to associated testing processes. These currently include: Performing Revenue Neutrality Testing to ensure expected revenue streams are largely unchanged from one period to	to the daily scrum file to indicate the environment where each defect was identified. 5. The SI vendor provides the total number of defects in production and reports these numbers regularly to BHA. 6. The project evaluate existing project	monitor R4.10, FHIR, any MSDs, and the AER solution. 2/28/25 - R4.10 was deployed to production on 2/6/2025. That same day, users reported a critical defect, prompting the deployment of a hotfix with a workaround on 2/7/2025. Following the deployment of R4.10, the project has recorded five additional unresolved production defects: two high severity, two medium severity, and one low severity, in Azure DevOps (ADO)—(see Appendix E for details). BHA is prioritizing higher-priority tasks, which has delayed addressing these lower-priority defects, though remediation efforts are underway. Additionally, the AER solution went live on 2/12/2025 and a Mid-Sprint Deployment (MSD) with 2 new items were deployed the same day. The R4.11 go-live is scheduled for 4/3/2025. IV&V remains concerned about code quality and will continue to monitor R4.10, FHIR, any MSDs, and the AER solution.									
			process of identifying improvements to associated testing processes. These currently include: Performing Revenue Neutrality Testing to ensure expected revenue streams are largely unchanged from one period to the next. Conducting	to the daily scrum file to indicate the environment where each defect was identified. 5. The SI vendor provides the total number of defects in production and reports these numbers regularly to BHA. 6. The project evaluate existing project staff skills and experience level to ensure they meet BHA support requirements.	monitor R4.10, FHIR, any MSDs, and the AER solution. 2/28/25 - R4.10 was deployed to production on 2/6/2025. That same day, users reported a critical defect, prompting the deployment of a hotifix with a workaround on 2/7/2025. Following the deployment of R4.10, the project has recorded five additional unresolved production defects: two high severity, two medium severity, and one low severity, in Azure DevOps (ADO)—(see Appendix E for details). BHA is prioritizing higher-priority tasks, which has delayed addressing these lower-priority defects, though remediation efforts are underway. Additionally, the AER solution went live on 2/21/2025 and a Mid-Sprint Deployment (MSD) with 2 new items were deployed the same day. The R4.11 go-live is scheduled for 4/3/2025. N&V remains concerned about code quality and will continue to monitor R4.10, FHIR, any MSDs, and the AER solution. 1/31/25 - The R4.10 go-live is scheduled for 2/6/2025. Currently, 25 unresolved production defects remain, including									
			process of identifying improvements to associated testing processes. These currently include: Performing Revenue Neutrality Testing to ensure expected revenue streams are largely unchanged from one period to	to the daily scrum file to indicate the environment where each defect was identified. 5. The SI vendor provides the total number of defects in production and reports these numbers regularly to BHA. 6. The project evaluate existing project staff skills and experience level to ensure	monitor R4.10, FHIR, any MSDs, and the AER solution. 2/28/25 - R4.10 was deployed to production on 2/6/2025. That same day, users reported a critical defect, prompting the deployment of a hotfix with a workaround on 2/7/2025. Following the deployment of R4.10, the project has recorded five additional unresolved production defects: two high severity, two medium severity, and one low severity, in Azure DevOps (ADO)—(see Appendix E for details). BHA is prioritizing higher-priority tasks, which has delayed addressing these lower-priority defects, though remediation efforts are underway. Additionally, the AER solution went live on 2/12/2025 and a Mid-Sprint Deployment (MSD) with 2 new items were deployed the same day. The R4.11 go-live is scheduled for 4/3/2025. IV&V remains concerned about code quality and will continue to monitor R4.10, FHIR, any MSDs, and the AER solution.									

ID	Short Description	Finding Statement	Analysis and	Recommendation	Finding Update	Category	Туре	Priority	Status	Closure Reason	Closed Date	Identified Date	Owner	
24	Limited BHA resources	Chartago of	Key BHA project	IV&V recommends that BHA implement	4/30/25 -To address a few of the resource challenges the project has faced, in early April 2025, DDD onboarded a	Resource	Issue	Medium	Open			8/18/2023	Michael Fors	
34	Ellitted Brix resources	Behavioral Health	resources have	a structured knowledge transfer process	Tosca Automated Regression Testing Subject Matter Expert (SME). To support a successful onboarding, DDD provided		13300	Wediam	Орен			0/10/2023	Wilchael FOI3	
		Administration (BHA)	reported constraints	when key personnel retire, including cross-	system demos, training materials, and facilitated collaboration with the CAMHD and SI team. Internal DDD resources	Management								
		project resources	on how much time	training and documenting critical	have been identified for knowledge transfer related to regression testing. This will enable an effective transition for									
		could lead to reduced		knowledge in the Dynamics Help Desk	maintaining the automated testing suite. Additionally, CAMHD and DDD are actively working to identify and secure									
		productivity and	project. The departure	system. Regular updates to the knowledge	resources to support the Business Analyst roles.									
	project delays.	project delays.	of the Child and	base will maintain its accuracy, preserve										
			Adolescent Mental	essential information, and support smooth	3/31/25 - BHA is actively documenting knowledge to manage staff transitions and reduce resource strain. The team is									
			Health Division	operational continuity.	creating knowledge transfer articles to capture key information, but some gaps remain. A key challenge is converting									
			(CAMHD) System		issues into clear, documented articles, as informal communication (emails, calls, or ad hoc discussions) can bypass									
			Management Office	Utilizing peer-to-peer knowledge	the help desk system. To improve consistency and visibility, BHA is working to ensure all relevant issues are properly									
			Manager and CAMHD		logged as help desk cases when appropriate. To further address the resourcing challenge, DDD will be onboarding a									
			Inspire Project Lead	members to informally share their	Tosca Automated Regression Testing Subject Matter Expert (SME) in early April 2025 to improve cross-training and									
			could further impact	expertise during team meetings.	support. The kickoff meeting took place on 3/17/25. As part of this project, PCG will work with DDD to identify the									
			the project if DOH cannot acquire	Additionally, creating internal documentation that outlines best practices	resources and processes for the ongoing maintenance of regression testing scripts. Additionally, training will be scheduled in May 2025.									
			suitable resources.	and processes for developing security	scheduled in May 2025.									
				policies would serve as a self-service	2/28/25 - BHA is developing a succession plan to address the potential departure of key personnel and is actively									
			the DOH test script	resource for the team.	working on having resources document knowledge as team members transition. This proactive approach aims to									
			developer has slowed	resource for the team.	ensure continuity and preserve essential information. One example of this effort is creating a knowledge base within									
			DOH's automated test	3. DDD and CAMHD have further	the Help Desk system in Dynamics, which serves as a centralized resource for troubleshooting and support processes.									
			script development.	discussions to optimize resource utilization	By documenting processes, workflows, and troubleshooting steps, BHA ensures that future staff can access the same									
			If BHA is unable to	between the two divisions.	information and continue operations smoothly, even as experienced team members move on.									
			fully staff the project											
			and their existing	4. BHA should explore options for	1/31/25 - IV&V was informed that some cross-training had been conducted, but concerns remain regarding the									
			resources continue to	offloading project team members' daily	insufficient knowledge transfer for critical tasks. While a limited amount of knowledge transfer occurred concerning									
			be constrained, the	responsibilities to other staff.	the provider portal, it was highlighted that more comprehensive cross-training is needed, particularly for the									
			project could		provider and customer portals. This would help reduce the risks associated with knowledge gaps and ensure									
			experience a	5. BHA should work quickly to create new	continuity in operations, especially in the event of key personnel unavailability. DDD plans to onboard a Tosca									
			reduction in	positions and receive State approval.	Automated Regression Testing Subject Matter Expert (SME) to address the resourcing issue and improve cross-									
			productivity and		training. The plans and timeline for Tosca automated regression testing are being reviewed, with plans to commence									
			project delays.	6. BHA should identify tasks and duties that	work on 3/1/2025.									
				they can ask the SI to assume, as permitted	12/31/24 - IV&V is concerned that limited resources at RHA could cause project delays and affect system quality. For									
39	Deployment process.	Due to on-going	Several post-	Implement a streamlined Root Cause	4/30/25 - R4.11 was successfully deployed on 4/3/2025, with Smoke Testing successfully completed on 4/4/25. A	Release/Deployment	Issue	Low	Open				Gautam Gulvady	
		deployment processes	production bugs have	Analysis (RCA) process to identify	Mid-Sprint Deployment (MSD) was also conducted on 4/18/25, which included four (4) User Stories. One earlier high-	Planning								
		and technical	been encountered in	deployment causes and prevent	severity defect was traced to a Microsoft service error and was resolved on 4/18/25. A second high-severity issue									
		execution issues, the	the Phase 4 release,	recurrence. To manage resource	was later identified as deployment-related. While an RCA was documented and shared via email, the issue was not									
		Project may continue	R4.4.	constraints, consider timeboxing RCA	logged in Azure DevOps (ADO) as per standard procedures and was instead tracked informally. Additional unresolved									
		to encounter defects	Regarding the bug,	efforts—e.g., 1–2 hours per defect or a set	production defects have been identified following the R4.11 deployment, and the project team is currently working									
		and challenges, e.g.,	"Human Services	number of hours weekly. Within this	to confirm the number of new defects. Root Cause Analyses (RCAs) are not currently being consistently documented									
		when releases are in	Research Institute	timeframe, focus on gathering context,	for production defects, and the project has yet to effectively leverage RCA findings to reduce post-production defect									
		production or in		analyzing causes, and proposing corrective										
		meeting projected timelines for	production" (bug# 34886	actions. Project PMs can track these actions to ensure follow-through.	planned. Implementing a robust RCA process may help reduce defect recurrence by addressing unresolved or unidentified root causes. IV&V will continue to monitor the deployment quality of R4.11, FHIR, MSDs, and the AER									
		production and non-	https://dev.azure.com	actions to ensure rollow-through.	solution to identify any deployment-related defects.									
		production and non-		2. The Project should consider automating	action to technify any deproyment related defects.						I			
		deployments.	A%20INSPIRE/ workit		3/31/25 - It remains unclear whether RCAs (Root Cause Analyses) are adequately documented for defects deployed									
		-,	ems/edit/34886),	increased efficiency, consistency, faster	into production, and whether the project is effectively utilizing RCAs to minimize post-production defects. BHA has									
			what is in	time to market, improved collaboration	indicated that resource constraints have impeded some RCA efforts. Neglecting to implement RCA processes could						1			
			development and	and reliability, scalability, version control	result in heightened defect rates, including recurring issues due to unidentified and/or unresolved root causes. With						I			
			deployed is vastly	integration, and rollback capability.	the R4.11 go-live scheduled for 4/3/25, IV&V will continue to monitor the deployment quality of R4.10, FHIR, MSDs,									
			different from what	1	and the AER solution to identify any deployment-related defects.									
			was deployed to	3. Ensure there are adequate and qualified										
			was deployed to			l .	1	I						
			production.	resources to support the c3urrent	2/28/25 - The R4.9 deployment-related defect is yet to be addressed. R4.10 was deployed to production on									
			production.	deployment processes. This may require	2/28/25 - The R4.9 deployment-related defect is yet to be addressed. R4.10 was deployed to production on 2/6/2025. That same day, users reported a critical defect, prompting the deployment of a hotfix with a workaround									
			production. The root cause for	deployment processes. This may require the support from RSM resources to provide	2/6/2025. That same day, users reported a critical defect, prompting the deployment of a hotfix with a workaround on 2/7/2025. Since the R4.10 deployment, five additional unresolved production defects have been logged in Azure									
			production. The root cause for these errors is	deployment processes. This may require the support from RSM resources to provide assistance and knowledge transfer for	2/6/2025. That same day, users reported a critical defect, prompting the deployment of a hotfix with a workaround on 2/7/2025. Since the R4.10 deployment, five additional unresolved production defects have been logged in Azure DevOps (ADO): two high severity, two medium severity, and one low severity. Their Root Cause Analysis (RCA) is a considerable of the construction of the constr									
			production. The root cause for these errors is currently being	deployment processes. This may require the support from RSM resources to provide assistance and knowledge transfer for some of the more complex deployment	2/6/2025. That same day, users reported a critical defect, prompting the deployment of a hotfix with a workaround on 2/7/2025. Since the R4.10 deployment, five additional unresolved production defects have been logged in Azure DevOps (ADO): two high severity, two medium severity, and no low severity. Their Root Cause Analysis (RCA) is still pending. Additionally, the AER solution went live on 2/21/2025, and a Mid-Sprint Deployment (MSD) with two (2)									
			production. The root cause for these errors is	deployment processes. This may require the support from RSM resources to provide assistance and knowledge transfer for	2/6/2025. That same day, users reported a critical defect, prompting the deployment of a hotfix with a workaround on 2/7/2025. Since the R4.10 deployment, five additional unresolved production defects have been logged in Azure DevOps (ADO): two high severity, two medium severity, and one low severity. Their Root Cause Analysis (RCA) is still pending, Additionally, the AER solution went live on 2/21/2025, and a Mid-Sprint Deployment (MSD) with two (2) new items were deployed the same day. The R4.11 go-live is scheduled for 4/3/2025. IV&V will continue to monitor									
			production. The root cause for these errors is currently being investigated.	deployment processes. This may require the support from RSM resources to provide assistance and knowledge transfer for some of the more complex deployment components.	2/6/2025. That same day, users reported a critical defect, prompting the deployment of a hotfix with a workaround on 2/7/2025. Since the R4.10 deployment, five additional unresolved production defects have been logged in Azure DevOps (ADO): two high severity, two medium severity, and no low severity. Their Root Cause Analysis (RCA) is still pending. Additionally, the AER solution went live on 2/21/2025, and a Mid-Sprint Deployment (MSD) with two (2)									
			production. The root cause for these errors is currently being investigated. Repeatable	deployment processes. This may require the support from RSM resources to provide assistance and knowledge transfer for some of the more complex deployment components. 4. As appropriate, consult with RSM on	2/6/2025. That same day, users reported a critical defect, prompting the deployment of a hotfix with a workaround on 2/7/2025. Since the R4.10 deployment, five additional unresolved production defects have been logged in Azure DevOps (ADD): two high severity, two medium severity, and noe low severity. Their Root Causes Analysis (RCA) is still pending. Additionally, the AER solution went live on 2/21/2025, and a Mid-Sprint Deployment (MSD) with two (2) new items were deployed the same day. The R4.11 go-live is scheduled for 4/3/2025. IV&V will continue to monitor the deployment quality of R4.10, FHIR, any MSDs, and the AER solution.									
			production. The root cause for these errors is currently being investigated. Repeatable documented release	deployment processes. This may require the support from RSM resources to provide assistance and knowledge transfer for some of the more complex deployment components. 4. As appropriate, consult with RSM on best practices that BHA could employ to	2/6/2025. That same day, users reported a critical defect, prompting the deployment of a hotfix with a workaround on 2/7/2025. Since the RA.10 deployment, five additional unresolved production defects have been logged in Azure DevOps (ADO): two high severity, two medium severity, and one low severity. Their Root Cause Analysis (RCA) still pending. Additionally, the AER solution went live on 2/21/2025, and a Mid-Sprint Deployment (MSD) with two (2) new items were deployed the same day. The RA11 go-live is scheduled for 4/3/2025. IV&V will continue to monitor the deployment quality of R4.10, FHIR, any MSDs, and the AER solution. 1/31/25 - R4.9 encountered deployment issues, prompting the creation of a defect in ADO. BHA is actively working to									
			production. The root cause for these errors is currently being investigated. Repeatable documented release and deployment and	deployment processes. This may require the support from RSM resources to provide assistance and knowledge transfer for some of the more complex deployment components. 4. As appropriate, consult with RSM on	2/6/2025. That same day, users reported a critical defect, prompting the deployment of a hotfix with a workaround on 2/7/2025. Since the R4.10 deployment, five additional unresolved production defects have been logged in Azure DevOps (ADD): two high severity, two medium severity, and one low severity. Their Root Cause Analysis (RCA) is still pending. Additionally, the AER solution went live on 2/21/2025, and a Mid-Sprint Deployment (MSD) with two (2) new items were deployed the same day. The R4.11 go-live is scheduled for 4/3/2025. IV&V will continue to monitor the deployment quality of R4.10, FHIR, any MSDs, and the AER solution. 1/31/25 - R4.9 encountered deployment issues, prompting the creation of a defect in ADO. BHA is actively working to resolve these issues involving missing web resources and workflows. The R4.10 go-live is scheduled for 2/6/2025. The									
			production. The root cause for these errors is currently being investigated. Repeatable documented release and deployment and resources experienced	deployment processes. This may require the support from RSM resources to provide assistance and knowledge transfer for some of the more complex deployment components. 4. As appropriate, consult with RSM on best practices that BHA could employ to support deployment.	2/6/2025. That same day, users reported a critical defect, prompting the deployment of a hotfix with a workaround on 2/7/2025. Since the R4.10 deployment, five additional unresolved production defects have been logged in Azure DevOps (ADD): two high severity, two medium severity, and noe low severity. Their Root Cause Analysis (RCA) is still pending. Additionally, the AER solution went live on 2/21/2025, and a Mid-Sprint Deployment (MSD) with two (2) new items were deployed the same day. The R4.11 go-live is scheduled for 4/3/2025. IV&V will continue to monitor the deployment quality of R4.10, FHIR, any MSDs, and the AER solution. 1/31/25 - R4.9 encountered deployment issues, prompting the creation of a defect in ADO. BHA is actively working to resolve these issues involving missing web resources and workflows. The R4.10 go-live is scheduled for 2/6/2025. The FHIR development was completed and deployed to production on 1/29/25, with delays due to issues related to									
			production. The root cause for these errors is currently being investigated. Repeatable documented release and deployment and	deployment processes. This may require the support from RSM resources to provide assistance and knowledge transfer for some of the more complex deployment components. 4. As appropriate, consult with RSM on best practices that BHA could employ to support deployment.	2/6/2025. That same day, users reported a critical defect, prompting the deployment of a hotfix with a workaround on 2/7/2025. Since the R4.10 deployment, five additional unresolved production defects have been logged in Azure DevOps (ADD): two high severity, two medium severity, and one low severity. Their Root Cause Analysis (RCA) is still pending. Additionally, the AER solution went live on 2/21/2025, and a Mid-Sprint Deployment (MSD) with two (2) new items were deployed the same day. The R4.11 go-live is scheduled for 4/3/2025. IV&V will continue to monitor the deployment quality of R4.10, FHIR, any MSDs, and the AER solution. 1/31/25 - R4.9 encountered deployment issues, prompting the creation of a defect in ADO. BHA is actively working to resolve these issues involving missing web resources and workflows. The R4.10 go-live is scheduled for 2/6/2025. The									

ID	Short Description	Finding Statement	Analysis and Significance	Recommendation	Finding Update	Category	Туре	Priority	Status	Closure Reason	Closed Date	Identified Date	Owner	
40	Limited testing	Limited testing	There is a limited	Make efforts to implement a streamlined	4/30/25 - R4.11 was successfully deployed on 4/3/2025, with Smoke Testing successfully completed on 4/4/25. A	Test Practice	Issue	Medium	Open			1/31/2024	Gautam Gulvady	
		processes can lead to	understanding of the	Root Cause Analysis (RCA) process to	Mid-Sprint Deployment (MSD) was also performed on 4/18/25, which included four (4) User Stories. Additional	Validation						-,,	,	
		poor-quality software,	testing processes and	identify the causes of defects and prevent	unresolved production defects have been identified following the R4.11 deployment, and the project team is									
		project delays and	the roles and	recurrence. Due to project resource	currently working to confirm the number of new defects. The project team continues to address other outstanding									
		extended user	responsibilities of	constraints, propose timeboxing RCA	production defects (see Appendix E for details). The project team has enhanced smoke test scripts to provide more									
		acceptance testing.	those involved in the	efforts for each defect introduced into	comprehensive coverage, including functionality such as the Provider Portal. To further strengthen quality assurance,									
			process. There is no	production. Timeboxing involves allocating	the project onboarded a Tosca automated regression testing expert in early April 2025, with work scheduled to begin									
			formal process for the	a fixed period (e.g., 1-2 hours per defect or	shortly thereafter. This regression testing effort is expected to span April and May 2025. The expert will focus on									
			development, review, and approval of test	a set number of hours per week) for focused Root Cause Analysis (RCA)	repairing existing Tosca scripts and reinitiating automated testing efforts.									
			scenarios, test cases,	activities. These activities may include	3/31/25 - The AER solution is in production. The project team closely monitored the solution to ensure stability,									
			and test results to		quickly resolve issues, and help users adjust to the new system (also known as Hypercare); Hypercare ended on									
			ensure adequate	potential causes, and proposing corrective	3/21/25 and the project is prioritizing the product backlog. The AER team worked diligently to close all defects									
			participation and	actions, all within the specified timeframe.	reported during Hypercare.									
			approval from state	Project PM(s) can oversee the tracking of	Since the deployment of R4.10 on 2/6/25, the project has identified additional unresolved production defects,									
			staff.	corrective actions to ensure completion.	including 1 high-severity defect, in Azure DevOps (ADO) (see Appendix E for details), despite testing at the unit.									
			When testing user		system integration (SIT), regression, joint, and smoke testing levels. In response, the System Integrator (SI) is									
			stories 34564 and	IV&V recommends that, after fixing a	enhancing smoke test scripts to provide more comprehensive coverage, including functionality such as the Provider									
			34756 on 1/31/24, the	defect, the SI incorporate relevant test	Portal. To further strengthen quality assurance, the project will be onboarding Tosca automated regression testing									
			test tasks did not	cases to validate these fixes in subsequent	expert in early April 2025, with work scheduled to begin subsequently. The expert will focus on repairing existing									
			reflect the real use	releases.	Tosca scripts and reinitiating automated testing efforts.									
			cases to give											
				IV&V has requested discussions on various	2/28/25 - R4.10 was deployed to production on 2/6/2025. Since the deployment of R4.10, five additional unresolved									
			confidence that the	aspects of the INSPIRE testing process with	production defects have been recorded in Azure DevOps (ADO) (see Appendix E for details): two high severity, two									
			user story could be	a focus on process such as tracking test	medium severity, and one low severity—despite testing at the unit, SIT, regression, joint, and smoke testing levels. In									
			tested. As a result,	coverage and requirements traceability,	response, the SI has committed to enhancing Smoke Test scripts to include more comprehensive testing, such as for									
			time was expended by	considering new development of Access	the Provider Portal.									
			testing resources,	Rules, Document management/digitization.	The project plans to onboard an Automated Regression Testing Tool (Tosca) expert, with work planned to begin									
			testing was		sometime in the month of March 2025. The project hopes to utilize this expert to repair their existing Tosca scripts so									
			inadequate, and a user story may have	A Stakeholder Register helps identify and understand all project stakeholders,	they can restart automated testing efforts. User Acceptance Testing for AER functionality was completed successfully with BHA approving the AER testing									
				ensuring their needs are met and risks are	deliverables. The AER solution went live on 2/21/2025.									
			functionality when it	managed through effective	deliverables. The Ach Solution went live on 2/21/2025.									
			did not	communication A RACI clarifies roles and	1/31/25 - IV&V has been requesting a walkthrough of the INSPIRE testing process since 10/2024, which the SI has not									
41	Backlog meetings	The absence of	Currently, product	Separate dedicated product backlog review	4/30/25 - IV&V was invited to attend the DDD Backlog Prioritization Meeting. Several key items were discussed,	Sprint Planning	Risk	Low	Open			1/26/2024	Gautam Gulvady	
		separate dedicated	backlog reviews are	meetings (during sprints) would allow	including:									
		product backlog	done during design	clarifying any ambiguities or uncertainties,										
		review meetings can			- Apple Health									
			meetings and/or	re-prioritization, estimation, and	- Calculator									
		lead to unclear	meetings and/or weekly issues	re-prioritization, estimation, and refinement of backlog items. This would	- Calculator - Provider and Customer Portal Documents									
		priorities,	meetings and/or weekly issues meetings. This can	re-prioritization, estimation, and refinement of backlog items. This would allow the project team to avoid situations	- Calculator - Provider and Customer Portal Documents While the meeting addressed these items, many of the backlog items still require estimation. DDD is currently									
		priorities, misalignment with	meetings and/or weekly issues meetings. This can lead to, e.g., scattered	re-prioritization, estimation, and refinement of backlog items. This would allow the project team to avoid situations where decisions about including items mid-	- Calculator - Provider and Customer Portal Documents While the meeting addressed these items, many of the backlog items still require estimation. DDD is currently working to complete these estimations. IV&V is reducing the risk rating from medium to low due to the progress									
		priorities, misalignment with stakeholders,	meetings and/or weekly issues meetings. This can lead to, e.g., scattered focus, limited	re-prioritization, estimation, and refinement of backlog items. This would allow the project team to avoid situations	- Calculator - Provider and Customer Portal Documents While the meeting addressed these items, many of the backlog items still require estimation. DDD is currently									
		priorities, misalignment with stakeholders, inadequate	meetings and/or weekly issues meetings. This can lead to, e.g., scattered focus, limited stakeholder	re-prioritization, estimation, and refinement of backlog items. This would allow the project team to avoid situations where decisions about including items mid- sprint would have to be taken.	- Calculator - Provider and Customer Portal Documents While the meeting addressed these items, many of the backlog items still require estimation. DDD is currently working to complete these estimations. IV&V is reducing the risk rating from medium to low due to the progress made in backlog prioritization and ongoing efforts to complete estimations.									
		priorities, misalignment with stakeholders, inadequate refinement, and	meetings and/or weekly issues meetings. This can lead to, e.g., scattered focus, limited stakeholder engagement, difficulty	re-prioritization, estimation, and refinement of backlog items. This would allow the project team to avoid situations where decisions about including items mid- sprint would have to be taken. IVV recommends scheduling separate	- Calculator - Provider and Customer Portal Documents While the meeting addressed these items, many of the backlog items still require estimation. DDD is currently working to complete these estimations. IV&V is reducing the risk rating from medium to low due to the progress made in backlog prioritization and ongoing efforts to complete estimations. 3/31/25- Product Backlog meetings are being scheduled, and the IV&V team has been invited to attend. These									
		priorities, misalignment with stakeholders, inadequate	meetings and/or weekly issues meetings. This can lead to, e.g., scattered focus, limited stakeholder engagement, difficulty in managing	re-prioritization, estimation, and refinement of backlog items. This would allow the project team to avoid situations where decisions about including items midsprint would have to be taken. IVV recommends scheduling separate dedicated product backlog review meetings	- Calculator - Provider and Customer Portal Documents While the meeting addressed these items, many of the backlog items still require estimation. DDD is currently working to complete these estimations. IV&V is reducing the risk rating from medium to low due to the progress made in backlog prioritization and ongoing efforts to complete estimations. 3/31/25- Product Backlog meetings are being scheduled, and the IV&V team has been invited to attend. These meetings are essential for aligning priorities, managing technical dependencies, and ensuring that backlog items are									
		priorities, misalignment with stakeholders, inadequate refinement, and increased risk of scope	meetings and/or weekly issues meetings. This can lead to, e.g., scattered focus, limited stakeholder engagement, difficulty in managing complexity, and	re-prioritization, estimation, and refinement of backlog items. This would allow the project team to avoid situations where decisions about including items mid- sprint would have to be taken. IVV recommends scheduling separate	- Calculator - Provider and Customer Portal Documents While the meeting addressed these items, many of the backlog items still require estimation. DDD is currently working to complete these estimations. IV&V is reducing the risk rating from medium to low due to the progress made in backlog prioritization and ongoing efforts to complete estimations. 3/31/25- Product Backlog meetings are being scheduled, and the IV&V team has been invited to attend. These									
		priorities, misalignment with stakeholders, inadequate refinement, and increased risk of scope	meetings and/or weekly issues meetings. This can lead to, e.g., scattered focus, limited stakeholder engagement, difficulty in managing	re-prioritization, estimation, and refinement of backlog items. This would allow the project team to avoid situations where decisions about including items mid- sprint would have to be taken. IVV recommends scheduling separate dedicated product backlog review meetings (during sprints) where all relevant	- Calculator - Provider and Customer Portal Documents While the meeting addressed these items, many of the backlog items still require estimation. DDD is currently working to complete these estimations. IV&V is reducing the risk rating from medium to low due to the progress made in backlog prioritization and ongoing efforts to complete estimations. 3/31/25- Product Backlog meetings are being scheduled, and the IV&V team has been invited to attend. These meetings are essential for aligning priorities, managing technical dependencies, and ensuring that backlog items are									
		priorities, misalignment with stakeholders, inadequate refinement, and increased risk of scope	meetings and/or weekly issues meetings. This can lead to, e.g., scattered focus, limited stakeholder engagement, difficulty in managing complexity, and delayed decision	re-prioritization, estimation, and refinement of backlog items. This would allow the project team to avoid situations where decisions about including items mid- sprint would have to be taken. IVV recommends scheduling separate dedicated product backlog review meetings (during sprints) where all relevant stakeholders are invited to review the	- Calculator - Provider and Customer Portal Documents While the meeting addressed these items, many of the backlog items still require estimation. DDD is currently working to complete these estimations. IV&V is reducing the risk rating from medium to low due to the progress made in backlog prioritization and ongoing efforts to complete estimations. 3/31/25- Product Backlog meetings are being scheduled, and the IV&V team has been invited to attend. These meetings are essential for aligning priorities, managing technical dependencies, and ensuring that backlog items are well-defined for development and testing, helping to maintain project velocity and minimize rework.									
		priorities, misalignment with stakeholders, inadequate refinement, and increased risk of scope	meetings and/or weekly issues meetings. This can lead to, e.g., scattered focus, limited stakeholder engagement, difficulty in managing complexity, and delayed decision making.	re-prioritization, estimation, and refinement of backlog items. This would allow the project team to avoid situations where decisions about including items midsprint would have to be taken. IVV recommends scheduling separate declicated product backlog review meetings (during sprints) where all relevant stakeholders are invited to review the product backlog and scheduled at the	- Calculator - Provider and Customer Portal Documents While the meeting addressed these items, many of the backlog items still require estimation. DDD is currently working to complete these estimations. IV&V is reducing the risk rating from medium to low due to the progress made in backlog prioritization and ongoing efforts to complete estimations. 3/31/25- Product Backlog meetings are being scheduled, and the IV&V team has been invited to attend. These meetings are essential for aligning priorities, managing technical dependencies, and ensuring that backlog items are well-defined for development and testing, helping to maintain project velocity and minimize rework. 2/28/25 - BHA plans to schedule other backlog review meetings and will notify IV&V accordingly. While some									
		priorities, misalignment with stakeholders, inadequate refinement, and increased risk of scope	meetings and/or weekly issues meetings. This can lead to, e.g., scattered focus, limited stakeholder engagement, difficulty in managing complexity, and delayed decision making. A product backlog review is an essential part of agile project	re-prioritization, estimation, and refinement of backlog items. This would allow the project team to avoid situations where decisions about including items midsprint would have to be taken. IV recommends scheduling separate dedicated product backlog review meetings (during sprints) where all relevant stakeholders are invited to review the product backlog and scheduled at the appropriate time(s) such that there is sufficient time to plan the design, development, and implementation (DDI) of	- Calculator - Provider and Customer Portal Documents While the meeting addressed these items, many of the backlog items still require estimation. DDD is currently working to complete these estimations. IV&V is reducing the risk rating from medium to low due to the progress made in backlog prioritization and ongoing efforts to complete estimations. 3/31/25- Product Backlog meetings are being scheduled, and the IV&V team has been invited to attend. These meetings are essential for aligning priorities, managing technical dependencies, and ensuring that backlog items are well-defined for development and testing, helping to maintain project velocity and minimize rework. 2/28/25 - BHA plans to schedule other backlog review meetings and will notify IV&V accordingly. While some meetings have already occurred, a consistent backlog review schedule is still being established. Efforts are also									
		priorities, misalignment with stakeholders, inadequate refinement, and increased risk of scope	meetings and/or weekly issues meetings. This can lead to, e.g., scattered focus, limited stakeholder engagement, difficulty in managing complexity, and delayed decision making. A product backlog review is an essential part of agile project management,	re-prioritization, estimation, and refinement of backlog items. This would allow the project team to avoid situations where decisions about including items mid- sprint would have to be taken. IVV recommends scheduling separate dedicated product backlog review meetings (during sprints) where all relevant stakeholders are invited to review the product backlog and scheduled at the appropriate time(s) such that there is sufficient time to plan the design,	- Calculator - Provider and Customer Portal Documents While the meeting addressed these items, many of the backlog items still require estimation. DDD is currently working to complete these estimations. IV&V is reducing the risk rating from medium to low due to the progress made in backlog prioritization and ongoing efforts to complete estimations. 3/31/25- Product Backlog meetings are being scheduled, and the IV&V team has been invited to attend. These meetings are essential for aligning priorities, managing technical dependencies, and ensuring that backlog items are well-defined for development and testing, helping to maintain project velocity and minimize rework. 2/28/25 - BHA plans to schedule other backlog review meetings and will notify IV&V accordingly. While some meetings have already occurred, a consistent backlog review schedule is still being established. Efforts are also underway to improve the backlog review process. Regular meetings and process enhancements will help ensure alignment, facilitate timely issue resolution, and keep the project moving forward efficiently.									
		priorities, misalignment with stakeholders, inadequate refinement, and increased risk of scope	meetings and/or weekly issues meetings. This can lead to, e.g., scattered focus, limited stakeholder engagement, difficulty in managing complexity, and delayed decision making. A product backlog review is an essential part of agile project management, particularly in Scrum.	re-prioritization, estimation, and refinement of backlog items. This would allow the project team to avoid situations where decisions about including items midsprint would have to be taken. IV recommends scheduling separate dedicated product backlog review meetings (during sprints) where all relevant stakeholders are invited to review the product backlog and scheduled at the appropriate time(s) such that there is sufficient time to plan the design, development, and implementation (DDI) of	- Calculator - Provider and Customer Portal Documents While the meeting addressed these items, many of the backlog items still require estimation. DDD is currently working to complete these estimations. IV&V is reducing the risk rating from medium to low due to the progress made in backlog prioritization and ongoing efforts to complete estimations. 3/31/25- Product Backlog meetings are being scheduled, and the IV&V team has been invited to attend. These meetings are essential for aligning priorities, managing technical dependencies, and ensuring that backlog items are well-defined for development and testing, helping to maintain project velocity and minimize rework. 2/28/25 - BHA plans to schedule other backlog review meetings and will notify IV&V accordingly. While some meetings have already occurred, a consistent backlog review schedule is still being established. Efforts are also underway to improve the backlog review process. Regular meetings and process enhancements will help ensure alignment, facilitate timely issue resolution, and keep the project moving forward efficiently. 1/31/25 - BHA remains satisfied with the backlog prioritization. However, CAMHD, having conducted surveys and									
		priorities, misalignment with stakeholders, inadequate refinement, and increased risk of scope	meetings and/or weekly issues meetings. This can lead to, e.g., scattered focus, limited stakeholder engagement, difficulty in managing complexity, and delayed decision making. A product backlog review is an essential part of agile project management, particularly in Scrum. It's a collaborative	re-prioritization, estimation, and refinement of backlog items. This would allow the project team to avoid situations where decisions about including items midsprint would have to be taken. IV recommends scheduling separate dedicated product backlog review meetings (during sprints) where all relevant stakeholders are invited to review the product backlog and scheduled at the appropriate time(s) such that there is sufficient time to plan the design, development, and implementation (DDI) of	- Calculator - Provider and Customer Portal Documents While the meeting addressed these items, many of the backlog items still require estimation. DDD is currently working to complete these estimations. IV&V is reducing the risk rating from medium to low due to the progress made in backlog prioritization and ongoing efforts to complete estimations. 3/31/25- Product Backlog meetings are being scheduled, and the IV&V team has been invited to attend. These meetings are essential for aligning priorities, managing technical dependencies, and ensuring that backlog items are well-defined for development and testing, helping to maintain project velocity and minimize rework. 2/28/25 - BHA plans to schedule other backlog review meetings and will notify IV&V accordingly. While some meetings have already occurred, a consistent backlog review schedule is still being established. Efforts are also underway to improve the backlog review process. Regular meetings and process enhancements will help ensure alignment, facilitate timely issue resolution, and keep the project moving forward efficiently. 1/31/25 - BHA remains satisfied with the backlog prioritization. However, CAMHD, having conducted surveys and user group interviews in 2019 and 2020, is concerned that gathering feedback from a broader user base might lead									
		priorities, misalignment with stakeholders, inadequate refinement, and increased risk of scope	meetings and/or weekly issues meetings. This can lead to, e.g., scattered focus, limited stakeholder engagement, difficulty in managing complexity, and delayed decision making. A product backlog review is an essential part of agile project management, particularly in Scrum. It's a collaborative meeting where the	re-prioritization, estimation, and refinement of backlog items. This would allow the project team to avoid situations where decisions about including items midsprint would have to be taken. IV recommends scheduling separate dedicated product backlog review meetings (during sprints) where all relevant stakeholders are invited to review the product backlog and scheduled at the appropriate time(s) such that there is sufficient time to plan the design, development, and implementation (DDI) of	- Calculator - Provider and Customer Portal Documents While the meeting addressed these items, many of the backlog items still require estimation. DDD is currently working to complete these estimations. IV&V is reducing the risk rating from medium to low due to the progress made in backlog prioritization and ongoing efforts to complete estimations. 3/31/25- Product Backlog meetings are being scheduled, and the IV&V team has been invited to attend. These meetings are essential for aligning priorities, managing technical dependencies, and ensuring that backlog items are well-defined for development and testing, helping to maintain project velocity and minimize rework. 2/28/25- BHA plans to schedule other backlog review meetings and will notify IV&V accordingly. While some meetings have already occurred, a consistent backlog review schedule is still being established. Efforts are also underway to improve the backlog review process. Regular meetings and process enhancements will help ensure alignment, facilitate timely issue resolution, and keep the project moving forward efficiently. 1/31/25 - BHA remains satisfied with the backlog prioritization. However, CAMHD, having conducted surveys and user group interviews in 2019 and 2020, is concerned that gathering feedback from a broader user base might lead to additional requests without proper prioritization. DDD mentioned that the next product backlog meeting is									
		priorities, misalignment with stakeholders, inadequate refinement, and increased risk of scope	meetings and/or weekly issues meetings. This can lead to, e.g., scattered focus, limited stakeholder engagement, difficulty in managing complexity, and delayed decision making. A product backlog review is an essential part of agile project management, particularly in Scrum. It's a collaborative meeting where the Scrum team, including	re-prioritization, estimation, and refinement of backlog items. This would allow the project team to avoid situations where decisions about including items midsprint would have to be taken. IV recommends scheduling separate dedicated product backlog review meetings (during sprints) where all relevant stakeholders are invited to review the product backlog and scheduled at the appropriate time(s) such that there is sufficient time to plan the design, development, and implementation (DDI) of	- Calculator - Provider and Customer Portal Documents While the meeting addressed these items, many of the backlog items still require estimation. DDD is currently working to complete these estimations. IV&V is reducing the risk rating from medium to low due to the progress made in backlog prioritization and ongoing efforts to complete estimations. 3/31/25- Product Backlog meetings are being scheduled, and the IV&V team has been invited to attend. These meetings are essential for aligning priorities, managing technical dependencies, and ensuring that backlog items are well-defined for development and testing, helping to maintain project velocity and minimize rework. 2/28/25 - BHA plans to schedule other backlog review meetings and prosess enhancements, underway to improve the backlog review schedule is still being established. Efforts are also underway to improve the backlog review process. Regular meetings and process enhancements will help ensure alignment, facilitate timely issue resolution, and keep the project moving forward efficiently. 1/31/25 - BHA remains satisfied with the backlog prioritization. However, CAMHD, having conducted surveys and user group interviews in 2019 and 2020, is concerned that gathering feedback from a broader user base might lead to additional requests without proper prioritization. DDD mentioned that the next product backlog meeting is scheduled for Monday, 2/2/2025, due to current team availability and ongoing commitments. Additionally, IV&V will									
		priorities, misalignment with stakeholders, inadequate refinement, and increased risk of scope	meetings and/or weekly issues meetings. This can lead to, e.g., scattered focus, limited stakeholder engagement, difficulty in managing complexity, and delayed decision making. A product backlog review is an essential part of agile project management, particularly in Scrum. It's a collaborative meeting where the Scrum team, including the Product Owner,	re-prioritization, estimation, and refinement of backlog items. This would allow the project team to avoid situations where decisions about including items midsprint would have to be taken. IV recommends scheduling separate dedicated product backlog review meetings (during sprints) where all relevant stakeholders are invited to review the product backlog and scheduled at the appropriate time(s) such that there is sufficient time to plan the design, development, and implementation (DDI) of	- Calculator - Provider and Customer Portal Documents While the meeting addressed these items, many of the backlog items still require estimation. DDD is currently working to complete these estimations. IV&V is reducing the risk rating from medium to low due to the progress made in backlog prioritization and ongoing efforts to complete estimations. 3/31/25- Product Backlog meetings are being scheduled, and the IV&V team has been invited to attend. These meetings are essential for aligning priorities, managing technical dependencies, and ensuring that backlog items are well-defined for development and testing, helping to maintain project velocity and minimize rework. 2/28/25- BHA plans to schedule other backlog review meetings and will notify IV&V accordingly. While some meetings have already occurred, a consistent backlog review schedule is still being established. Efforts are also underway to improve the backlog review process. Regular meetings and process enhancements will help ensure alignment, facilitate timely issue resolution, and keep the project moving forward efficiently. 1/31/25 - BHA remains satisfied with the backlog prioritization. However, CAMHD, having conducted surveys and user group interviews in 2019 and 2020, is concerned that gathering feedback from a broader user base might lead to additional requests without proper prioritization. DDD mentioned that the next product backlog meeting is									
		priorities, misalignment with stakeholders, inadequate refinement, and increased risk of scope	meetings and/or weekly issues meetings. This can lead to, e.g., scattered focus, limited stakeholder engagement, difficulty in managing complexity, and delayed decision making. A product backlog review is an essential part of agile project management, particularly in Scrum. It's a collaborative meeting where the Scrum team, including the Product Owner, Scrum Master, and	re-prioritization, estimation, and refinement of backlog items. This would allow the project team to avoid situations where decisions about including items midsprint would have to be taken. IV recommends scheduling separate dedicated product backlog review meetings (during sprints) where all relevant stakeholders are invited to review the product backlog and scheduled at the appropriate time(s) such that there is sufficient time to plan the design, development, and implementation (DDI) of	- Calculator - Provider and Customer Portal Documents While the meeting addressed these items, many of the backlog items still require estimation. DDD is currently working to complete these estimations. IV&V is reducing the risk rating from medium to low due to the progress made in backlog prioritization and ongoing efforts to complete estimations. 3/31/25- Product Backlog meetings are being scheduled, and the IV&V team has been invited to attend. These meetings are essential for aligning priorities, managing technical dependencies, and ensuring that backlog items are well-defined for development and testing, helping to maintain project velocity and minimize rework. 2/28/25 - BHA plans to schedule other backlog review meetings and voil notify IV&V accordingly. While some meetings have already occurred, a consistent backlog review schedule is still being established. Efforts are also underway to improve the backlog review process. Regular meetings and process enhancements will help ensure alignment, facilitate timely issue resolution, and keep the project moving forward efficiently. 1/31/25 - BHA remains satisfied with the backlog prioritization. However, CAMHD, having conducted surveys and user group interviews in 2019 and 2020, is concerned that gathering feedback from a broader user base might lead to additional requests without proper prioritization. DDD mentioned that the next product backlog meeting is scheduled for Monday, 2/2/2025, due to current team availability and ongoing commitments. Additionally, IV&V will be invited to attend these backlog meetings.									
		priorities, misalignment with stakeholders, inadequate refinement, and increased risk of scope	meetings and/or weekly issues meetings. This can lead to, e.g., scattered focus, limited stakeholder engagement, difficulty in managing complexity, and delayed decision making. A product backlog review is an essential part of agile project management, particularly in Scrum, particularly in Scrum; te's a collaborative meeting where the Scrum team, including the Product Owner, Scrum Master, and development team	re-prioritization, estimation, and refinement of backlog items. This would allow the project team to avoid situations where decisions about including items midsprint would have to be taken. IV recommends scheduling separate dedicated product backlog review meetings (during sprints) where all relevant stakeholders are invited to review the product backlog and scheduled at the appropriate time(s) such that there is sufficient time to plan the design, development, and implementation (DDI) of	- Calculator - Provider and Customer Portal Documents While the meeting addressed these items, many of the backlog items still require estimation. DDD is currently working to complete these estimations. IV&V is reducing the risk rating from medium to low due to the progress made in backlog prioritization and ongoing efforts to complete estimations. 3/31/25- Product Backlog meetings are being scheduled, and the IV&V team has been invited to attend. These meetings are essential for aligning priorities, managing technical dependencies, and ensuring that backlog items are well-defined for development and testing, helping to maintain project velocity and minimize rework. 2/28/25 - BHA plans to schedule other backlog review meetings and will notify IV&V accordingly. While some meetings have already occurred, a consistent backlog review schedule is still being established. Efforts are also underway to improve the backlog review process. Regular meetings and process enhancements will help ensure alignment, facilitate timely issue resolution, and keep the project moving forward efficiently. 1/31/25 - BHA remains satisfied with the backlog prioritization. However, CAMHD, having conducted surveys and user group interviews in 2019 and 2020, is concerned that gathering feedback from a broader user base might lead to additional requests without proper prioritization. DDD mentioned that the next product backlog meeting is scheduled for Monday, 2/2/2025, due to current team availability and ongoing commitments. Additionally, IV&V will be invited to attend these backlog meetings.									
		priorities, misalignment with stakeholders, inadequate refinement, and increased risk of scope	meetings and/or weekly issues meetings. This can lead to, e.g., scattered focus, limited stakeholder engagement, difficulty in managing complexity, and delayed decision making. A product backlog review is an essential part of agile project management, particularly in Scrum, lat's a collaborative meeting where the Scrum team, including the Product Owner, Scrum Master, and development team members, inspect and	re-prioritization, estimation, and refinement of backlog items. This would allow the project team to avoid situations where decisions about including items midsprint would have to be taken. IV recommends scheduling separate dedicated product backlog review meetings (during sprints) where all relevant stakeholders are invited to review the product backlog and scheduled at the appropriate time(s) such that there is sufficient time to plan the design, development, and implementation (DDI) of	- Calculator - Provider and Customer Portal Documents While the meeting addressed these items, many of the backlog items still require estimation. DDD is currently working to complete these estimations. IV&V is reducing the risk rating from medium to low due to the progress made in backlog prioritization and ongoing efforts to complete estimations. 3/31/25- Product Backlog meetings are being scheduled, and the IV&V team has been invited to attend. These meetings are essential for aligning priorities, managing technical dependencies, and ensuring that backlog items are well-defined for development and testing, helping to maintain project velocity and minimize rework. 2/28/25 - BHA plans to schedule other backlog review meetings and will notify IV&V accordingly. While some meetings have already occurred, a consistent backlog review schedule is still being established. Efforts are also underway to improve the backlog review process. Regular meetings and process enhancements will help ensure alignment, facilitate timely issue resolution, and keep the project moving forward efficiently. 1/31/25 - BHA remains satisfied with the backlog prioritization. However, CAMHD, having conducted surveys and user group interviews in 2019 and 2020, is concerned that gathering feedback from a broader user base might lead to additional requests without proper prioritization. DDD mentioned that the next product backlog meeting is scheduled for Monday, 2/2/2025, due to current team availability and ongoing commitments. Additionally, IV&V will be invited to attend these backlog meetings.									
		priorities, misalignment with stakeholders, inadequate refinement, and increased risk of scope	meetings and/or weekly issues meetings. This can lead to, e.g., scattered focus, limited stakeholder engagement, difficulty in managing complexity, and delayed decision making. A product backlog review is an essential part of agile project management, particularly in Scrum. It's a collaborative meeting where the Scrum team, including the Product Owner, Scrum Master, and development team members, inspect and adapt the product	re-prioritization, estimation, and refinement of backlog items. This would allow the project team to avoid situations where decisions about including items midsprint would have to be taken. IV recommends scheduling separate dedicated product backlog review meetings (during sprints) where all relevant stakeholders are invited to review the product backlog and scheduled at the appropriate time(s) such that there is sufficient time to plan the design, development, and implementation (DDI) of	calculator Provider and Customer Portal Documents While the meeting addressed these items, many of the backlog items still require estimation. DDD is currently working to complete these estimations. IV&V is reducing the risk rating from medium to low due to the progress made in backlog prioritization and ongoing efforts to complete estimations. 3/31/25- Product Backlog meetings are being scheduled, and the IV&V team has been invited to attend. These meetings are essential for aligning priorities, managing technical dependencies, and ensuring that backlog items are well-defined for development and testing, helping to maintain project velocity and minimize rework. 2/28/25 - BHA plans to schedule other backlog review meetings and will notify IV&V accordingly. While some meetings have already occurred, a consistent backlog review schedule is still being established. Efforts are also underway to improve the backlog review process. Regular meetings and process enhancements will help ensure alignment, facilitate timely issue resolution, and keep the project moving forward efficiently. 1/31/25 - BHA remains satisfied with the backlog prioritization. However, CAMHD, having conducted surveys and user group interviews in 2019 and 2020, is concerned that gathering feedback from a broader user base might lead to additional requests without proper prioritization. DDD mentioned that the next product backlog meeting is scheduled for Monday, 2/2/2025, due to current team availability and ongoing commitments. Additionally, IV&V will be invited to attend these backlog meeting is scheduled for Monday, 2/2/2025, due to current team availability and ongoing commitments. Additionally, IV&V will be invited to attend these backlog meeting is a scheduled for Monday, 2/2/2025, due to current team availability and ongoing commitments. Additionally, IV&V will be invited to attend these backlog meeting is a scheduled for Monday, 2/2/2025, due to current team availability and ongoing commitments. Additionally, IV&V will be invited to atte									
		priorities, misalignment with stakeholders, inadequate refinement, and increased risk of scope	meetings and/or weekly issues meetings. This can lead to, e.g., scattered focus, limited stakeholder engagement, difficulty in managing complexity, and delayed decision making. A product backlog review is an essential part of agile project management, particularly in Scrum, lat's a collaborative meeting where the Scrum team, including the Product Owner, Scrum Master, and development team members, inspect and	re-prioritization, estimation, and refinement of backlog items. This would allow the project team to avoid situations where decisions about including items midsprint would have to be taken. IV recommends scheduling separate dedicated product backlog review meetings (during sprints) where all relevant stakeholders are invited to review the product backlog and scheduled at the appropriate time(s) such that there is sufficient time to plan the design, development, and implementation (DDI) of	- Calculator - Provider and Customer Portal Documents While the meeting addressed these items, many of the backlog items still require estimation. DDD is currently working to complete these estimations. IV&V is reducing the risk rating from medium to low due to the progress made in backlog prioritization and ongoing efforts to complete estimations. 3/31/25- Product Backlog meetings are being scheduled, and the IV&V team has been invited to attend. These meetings are essential for aligning priorities, managing technical dependencies, and ensuring that backlog items are well-defined for development and testing, helping to maintain project velocity and minimize rework. 2/28/25 - BHA plans to schedule other backlog review meetings and will notify IV&V accordingly. While some meetings have already occurred, a consistent backlog review schedule is still being established. Efforts are also underway to improve the backlog review process. Regular meetings and process enhancements will help ensure alignment, facilitate timely issue resolution, and keep the project moving forward efficiently. 1/31/25 - BHA remains satisfied with the backlog prioritization. However, CAMHD, having conducted surveys and user group interviews in 2019 and 2020, is concerned that gathering feedback from a broader user base might lead to additional requests without proper prioritization. DDD mentioned that the next product backlog meeting is scheduled for Monday, 2/2/2025, due to current team availability and ongoing commitments. Additionally, IV&V will be invited to attend these backlog meetings. 12/31/24-IV&V observed two CAMHD backlog prioritization meetings and will continue to monitor the process regularly. While CAMHD and DDD are generally satisfied with the backlog prioritization, there are areas for improvement, particularly in balancing input from a broader user base and ensuring that federal compliance and performance-related features are given appropriate attention in the backlog. gy refining these sapects, both teams									
		priorities, misalignment with stakeholders, inadequate refinement, and increased risk of scope	meetings and/or weekly issues meetings. This can lead to, e.g., scattered focus, limited stakeholder engagement, difficulty in managing complexity, and delayed decision making. A product backlog review is an essential part of agile project management, particularly in Scrum. It's a collaborative meeting where the Scrum team, including the Product Owner, Scrum Master, and development team members, inspect and adapt the product backlog.	re-prioritization, estimation, and refinement of backlog items. This would allow the project team to avoid situations where decisions about including items midsprint would have to be taken. IV recommends scheduling separate dedicated product backlog review meetings (during sprints) where all relevant stakeholders are invited to review the product backlog and scheduled at the appropriate time(s) such that there is sufficient time to plan the design, development, and implementation (DDI) of	calculator Provider and Customer Portal Documents While the meeting addressed these items, many of the backlog items still require estimation. DDD is currently working to complete these estimations. IV&V is reducing the risk rating from medium to low due to the progress made in backlog prioritization and ongoing efforts to complete estimations. 3/31/25- Product Backlog meetings are being scheduled, and the IV&V team has been invited to attend. These meetings are essential for aligning priorities, managing technical dependencies, and ensuring that backlog items are well-defined for development and testing, helping to maintain project velocity and minimize rework. 2/28/25 - BHA plans to schedule other backlog review meetings and will notify IV&V accordingly. While some meetings have already occurred, a consistent backlog review schedule is still being established. Efforts are also underway to improve the backlog review process. Regular meetings and process enhancements will help ensure alignment, facilitate timely issue resolution, and keep the project moving forward efficiently. 1/31/25 - BHA remains satisfied with the backlog prioritization. However, CAMHD, having conducted surveys and user group interviews in 2019 and 2020, is concerned that gathering feedback from a broader user base might lead to additional requests without proper prioritization. DDD mentioned that the next product backlog meeting is scheduled for Monday, 2/2/2025, due to current team availability and ongoing commitments. Additionally, IV&V will be invited to attend these backlog meeting is scheduled for Monday, 2/2/2025, due to current team availability and ongoing commitments. Additionally, IV&V will be invited to attend these backlog meeting is a scheduled for Monday, 2/2/2025, due to current team availability and ongoing commitments. Additionally, IV&V will be invited to attend these backlog meeting is a scheduled for Monday, 2/2/2025, due to current team availability and ongoing commitments. Additionally, IV&V will be invited to atte									
		priorities, misalignment with stakeholders, inadequate refinement, and increased risk of scope	meetings and/or weekly issues meetings. This can lead to, e.g., scattered focus, limited stakeholder engagement, difficulty in managing complexity, and delayed decision making. A product backlog review is an essential part of agile project management, particularly in Scrum. It's a collaborative meeting where the Scrum team, including the Product Owner, Scrum Master, and development team members, inspect and adapt the product	re-prioritization, estimation, and refinement of backlog items. This would allow the project team to avoid situations where decisions about including items midsprint would have to be taken. IV recommends scheduling separate dedicated product backlog review meetings (during sprints) where all relevant stakeholders are invited to review the product backlog and scheduled at the appropriate time(s) such that there is sufficient time to plan the design, development, and implementation (DDI) of	- Calculator - Provider and Customer Portal Documents While the meeting addressed these items, many of the backlog items still require estimation. DDD is currently working to complete these estimations. IV&V is reducing the risk rating from medium to low due to the progress made in backlog prioritization and ongoing efforts to complete estimations. 3/31/25- Product Backlog meetings are being scheduled, and the IV&V team has been invited to attend. These meetings are essential for aligning priorities, managing technical dependencies, and ensuring that backlog items are well-defined for development and testing, helping to maintain project velocity and minimize rework. 2/28/25 - BHA plans to schedule other backlog review meetings and will notify IV&V accordingly. While some meetings have already occurred, a consistent backlog review schedule is still being established. Efforts are also underway to improve the backlog review process. Regular meetings and process enhancements will help ensure alignment, facilitate timely issue resolution, and keep the project moving forward efficiently. 1/31/25 - BHA remains satisfied with the backlog prioritization. However, CAMHD, having conducted surveys and user group interviews in 2019 and 2020, is concerned that gathering feedback from a broader user base might lead to additional requests without proper prioritization. DDD mentioned that the next product backlog meeting is scheduled for Monday, 2/2/2025, due to current team availability and ongoing commitments. Additionally, IV&V will be invited to attend these backlog meetings. 12/31/24-IV&V observed two CAMHD backlog prioritization meetings and will continue to monitor the process regularly. While CAMHD and DDD are generally satisfied with the backlog prioritization, there are areas for improvement, particularly in balancing input from a broader user base and ensuring that federal compliance and performance-related features are given appropriate attention in the backlog. gy refining these sapects, both teams									
		priorities, misalignment with stakeholders, inadequate refinement, and increased risk of scope	meetings and/or weekly issues meetings. This can lead to, e.g., scattered focus, limited stakeholder engagement, difficulty in managing complexity, and delayed decision making. A product backlog review is an essential part of agile project management, particularly in Scrum, lit's a collaborative meeting where the Scrum team, including the Product Owner, Scrum Master, and development team members, inspect and adapt the product backlog review is an important	re-prioritization, estimation, and refinement of backlog items. This would allow the project team to avoid situations where decisions about including items midsprint would have to be taken. IV recommends scheduling separate dedicated product backlog review meetings (during sprints) where all relevant stakeholders are invited to review the product backlog and scheduled at the appropriate time(s) such that there is sufficient time to plan the design, development, and implementation (DDI) of	calculator Provider and Customer Portal Documents While the meeting addressed these items, many of the backlog items still require estimation. DDD is currently working to complete these estimations. IV&V is reducing the risk rating from medium to low due to the progress made in backlog prioritization and ongoing efforts to complete estimations. 3/31/25- Product Backlog meetings are being scheduled, and the IV&V team has been invited to attend. These meetings are essential for aligning priorities, managing technical dependencies, and ensuring that backlog items are well-defined for development and testing, helping to maintain project velocity and minimize rework. 2/28/25- BHA plans to schedule other backlog review meetings and will notify IV&V accordingly. While some meetings have already occurred, a consistent backlog review schedule is still being established. Efforts are also underway to improve the backlog review process. Regular meetings and process enhancements will help ensure alignment, facilitate timely issue resolution, and keep the project moving forward efficiently. 1/31/25- BHA remains satisfied with the backlog prioritization. However, CAMHD, having conducted surveys and user group interviews in 2019 and 2020, is concerned that gathering feedback from a broader user base might lead to additional requests without proper prioritization. DDD mentioned that the next product backlog meeting is scheduled for Monday, 2/2/2025, due to current team availability and ongoing commitments. Additionally, IV&V will be invited to attend these backlog meetings. 1/231/24-IV&V observed two CAMHD backlog prioritization meetings and will continue to monitor the process regularly. While CAMHD and DDD are generally satisfied with the backlog prioritization, there are areas for improvement, particularly in balancing input from a broader user base and ensuring that federal compliance and performance-related features are given appropriate attention in the backlog. By refining these aspects, both teams can improve the ba									
		priorities, misalignment with stakeholders, inadequate refinement, and increased risk of scope	meetings and/or weekly issues meetings. This can lead to, e.g., scattered focus, limited stakeholder engagement, difficulty in managing complexity, and delayed decision making. A product backlog review is an essential part of agile project management, it's a collaborative meeting where the Scrum team, including the Product Owner, Scrum Master, and development team members, inspect and adapt the product backlog. The product backlog	re-prioritization, estimation, and refinement of backlog items. This would allow the project team to avoid situations where decisions about including items midsprint would have to be taken. IV recommends scheduling separate dedicated product backlog review meetings (during sprints) where all relevant stakeholders are invited to review the product backlog and scheduled at the appropriate time(s) such that there is sufficient time to plan the design, development, and implementation (DDI) of	- Calculator - Provider and Customer Portal Documents While the meeting addressed these items, many of the backlog items still require estimation. DDD is currently working to complete these estimations. IV&V is reducing the risk rating from medium to low due to the progress made in backlog prioritization and ongoing efforts to complete estimations. 3/31/25- Product Backlog meetings are being scheduled, and the IV&V team has been invited to attend. These meetings are essential for aligning priorities, managing technical dependencies, and ensuring that backlog items are well-defined for development and testing, helping to maintain project velocity and minimize rework. 2/28/25 - BHA plans to schedule other backlog review meetings and will notify IV&V accordingly. While some meetings have already occurred, a consistent backlog review schedule is still being established. Efforts are also underway to improve the backlog review process. Regular meetings and process enhancements will help ensure alignment, facilitate timely issue resolution, and keep the project moving forward efficiently. 1/31/25 - BHA remains satisfied with the backlog prioritization. However, CAMHD, having conducted surveys and user group interviews in 2019 and 2020, is concerned that gathering feedback from a broader user base might lead to additional requests without proper prioritization. DDD mentioned that the next product backlog meeting is scheduled for Monday, 2/2/2025, due to current team availability and ongoing commitments. Additionally, IV&V will be invited to attend these backlog meetings. 12/31/24 -IV&V observed two CAMHD backlog prioritization meetings and will continue to monitor the process regularly. While CAMHD and DDD are generally satisfied with the backlog prioritization, there are areas for improvement, particularly in balancing input from a broader user base and ensuring that federal compliance and performance-related features are given appropriate attention in the backlog. By refining these aspects, both teams can improve									

ID	Short Description	Finding Statement	Analysis and Significance	Recommendation	Finding Update	Category	Туре	Priority	Status	Closure Reason	Closed Date	Identified Date	Owner	
46	46 Defect management.	Neglecting the		IV&V recommends to:	4/30/25 - IV&V has reviewed the documentation outlining the Help Desk process. IV&V continues to observe	Project Management	Issue	Medium	Open			9/30/2024	Gautam Gulvady	
		established defect		1. The project records the history of a	increased project focus on both the Help Desk and defect management processes, and will monitor adherence to	, ,			· ·				,	
		management process		defect's severity in the corresponding	these processes while providing feedback and recommendations based on best practices Meanwhile, BHA is									
		could lead to		ticket's description/notes section in ADO.	reviewing the previously provided Help Desk documentation and considering adopting and enforcing the outlined									
		lost/forgotten defects,		For example, when a hotfix is deployed to	defect management procedures.									
		user frustration, and		mitigate a defect initially classified as										
		could slow resolution		"Critical," the description/notes section	3/31/25 - In March 2025, the SI provided documentation that was originally created in 2019, outlining the Help Desk									
		of similar defects in		should document that the defect originally	process. IV&V is continuing its review of the process and will provide feedback and recommendations based on best									
		the future.		had a "Critical" severity rating.	practices in April 2025. Notably, the project has placed increased attention on this area, which is a positive									
				2. Based on Best Practice wipdating the	development. As a result of this heightened focus, IV&V has observed a corresponding rise in the number of defects									
				defect management documentation and	being logged in Azure DevOps (ADO), indicating stronger adherence to reporting protocols and greater transparency									
				having regular refresher training on the	in issue tracking. Productive discussions are underway to address critical defects. By reviewing the Help Desk process									
				defect management process.	and addressing any gaps, IV&V anticipates improvements in the overall defect management approach. BHA usually									
				2. Send communications to the project	receives issues by email or helpdesk calls, with most reports submitted by email. Depending on the severity of the									
				stakeholders to clarify the defect	defect, BHA personnel may consult with other team members and flag high-severity defects, reporting them to the SI									
				management process and the importance	While the current process is generally effective, there is room to speed up how critical defects are handled,									
				of logging all defects.	particularly by enhancing how these issues are initially logged.									
				3. Take steps to assure current and new										
					2/28/25 - A high-priority defect occurred on 2/6/2025, bringing to light an opportunity to strengthen the project's									
				defects.	defect management process. BHA encountered some challenges that resulted in a delay in addressing the defect. In									
				Consider designating a defect	February, there were productive discussions on addressing critical defects. The SI has provided a document outlining									
				management lead or champion to oversee	the Help Desk process, which IV&V will review in March 2025 to further determine the risk.									
				adherence to the process and assure all	1/21/25 Division this according posted there continues to be a delevis according tiglists in Asian Davidos (ADO) for									
				defects are logged. 5. Keep stakeholders informed about	1/31/25 - During this reporting period, there continues to be a delay in creating tickets in Azure DevOps (ADO) for defects. IV&V remains concerned about the project's deviation from the Defect Management process. IV&V, BHA and									
				defect status, priority, impacts, and	the SI will continue discussions to identify process gaps and determine next steps.									
				resolution timelines. This could increase	the SI will continue discussions to identify process gaps and determine next steps.									
				awareness of the importance of logging	12/31/24 - During this reporting period, users encountered production issues related to the Calculator, including an									
				defects	inability to view active cases and resolved cases. However, the corresponding tickets were not promptly created in									
				6. Discuss ways to improve the defect	Azure DevOps (ADO), IV&V remains concerned about the project's non-adherence to the Defect Management									
				logging and management process with the	process. IV&V and BHA will continue discussions to identify process gaps and determine next steps.									
				SI and come up with a plan to improve.	process, was and other will continue diseassions to definity process gaps and determine next steps.									
				and a series of the series of	11/30/2024 - In recent meetings with DDD and CAMHD, IV&V discussed the issue of some defects reported to the									
					Helpdesk via phone or other channels not being logged or addressed. DDD noted that staff find the process of logging									
47	Production restarts.	The lack of a		IV&V recommends BHA	4/30/25 - BHA is continuing with the development of a document describing a communication protocol. BHA has	Project Management	Issue	Medium	Open			9/30/2024	Gautam Gulvady	
		governance process		1. Develop standard procedures for system										
		for restarting		restarts, including a checklist to determine	language preferences, which would further strengthen the protocol and enhance its effectiveness. BHA shared the									
		production systems		when a restart is necessary, pre-checks,	draft document with DDD and IV&V for initial review.									
		can impact service		step-by-step instructions, and post-restart										
		availability and		verifications.	3/31/25 - Based on discussions with key members of the deployment team, IV&V continues to recommend									
		frustrate end-users		Require formal approvals before	documenting processes, procedures, and communication protocols to eliminate ambiguity and promote a shared									
		and hinder		initiating a restart, especially for INSPIRE,	understanding among stakeholders. The deployment team is currently finalizing a communication protocol.									
		accountability.		and document all actions in a centralized										
				system.	2/28/25 - There has been no progress for this reporting period.									
				3. Define clear escalation paths for when	4/04/05 11/1									
				restarts do not go as planned, including	1/31/25 - When an issue requiring a production Portal restart occurred only once, certain project stakeholders									
				identifying contacts for technical support and management approval for additional	convened to discuss and implement the necessary steps. IV&V recommends documenting the actions taken during									
				and management approval for additional	that meeting as part of the process for production system restarts. Documenting processes and procedures removes ambiguity and ensures a common understanding among stakeholders.									
				Automate Restart Procedures where	ambiguity and ensures a common understanding among stakeholders.									
				possible.	13/21/24 BHA suggested that the deployment team or the Help Deck team may be hest suited to desument the									
			1	5. The governance process is established, it	12/31/24 - BHA suggested that the deployment team or the Help Desk team may be best suited to document the process. IV&V remains concerned that no further progress has been made and will continue to make				1					
						1	1		1			1		
				should be effectively communicated to the	recommendations on how BHA could resolve this issue and be prepared for a production restart.									
				should be effectively communicated to the project team.	recommendations on how BHA could resolve this issue and be prepared for a production restart.									
				should be effectively communicated to the project team. 6. Provide stakeholders with a clear										
				should be effectively communicated to the project team. 6. Provide stakeholders with a clear explanation of the reason for the restart	recommendations on how BHA could resolve this issue and be prepared for a production restart. 11/30/24 - No progress has been made for this reporting period.									
				should be effectively communicated to the project team. 6. Provide stakeholders with a clear explanation of the reason for the restart and the lessons learned, while	recommendations on how BHA could resolve this issue and be prepared for a production restart.									
				should be effectively communicated to the project team. 6. Provide stakeholders with a clear explanation of the reason for the restart and the lessons learned, while documenting the restart details in the	recommendations on how BHA could resolve this issue and be prepared for a production restart. 11/30/24 - No progress has been made for this reporting period.									
				should be effectively communicated to the project team. 6. Provide stakeholders with a clear explanation of the reason for the restart and the lessons learned, while	recommendations on how BHA could resolve this issue and be prepared for a production restart. 11/30/24 - No progress has been made for this reporting period.									
				should be effectively communicated to the project team. 6. Provide stakeholders with a clear explanation of the reason for the restart and the lessons learned, while documenting the restart details in the	recommendations on how BHA could resolve this issue and be prepared for a production restart. 11/30/24 - No progress has been made for this reporting period.									